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Dengue virus (DENV) serotypes 1-4 are mosquito-borne flaviviruses that 
are increasingly being diagnosed from travellers returning from journeys to 
subtropical and tropical regions. This is partly correlated with increasing 
numbers of travellers visiting endemic areas, to an increase in outbreak 
frequencies and to the continuing geographical spread of dengue viruses. At 
present, 50-100 cases of dengue infections are diagnosed annually in 
Finland. A mosquito-borne flavivirus closely related to DENV, Zika virus 
(ZIKV), was, for many years, considered to be a relatively harmless virus 
found in Africa and Asia, with low case numbers and mild disease 
associations. Since 2013, however, Zika virus has emerged and swept across 
Polynesia, the Americas and the Caribbean, causing massive outbreaks with 
new severe complications becoming apparent. Amongst these new 
complications, neurological symptoms have been observed in adults and, 
alarmingly, congenital infections resulting in severe developmental 
disorders, including microcephaly. 
The global expansion of these mosquito-borne flaviviruses is most likely 
due to a combination of factors including globalization and environmental 
changes, including the climate change. Such changes have enabled two 
important vector mosquito species, Aedes (Stegomyia) aegypti and Aedes 
(Stegomyia) albopictus, to spread into formerly uncolonised areas. This is 
particularly visible for Ae. albopictus, a strongly invasive species originating 
from Asia, which is currently expanding its distribution in Southern and 
Central Europe. Temporary populations have been reported from 
commercial greenhouses in the Netherlands, highlighting the possibility of 
expansion into more northerly countries. Areas with competent mosquito-
vectors are at risk for endemic transmission of mosquito-borne viruses, 
which can be introduced by viremic travellers. Europe has already 
experienced limited autochthonous dengue outbreaks during this 
Millennium in Croatia and France and a major outbreak in Madeira, 
Portugal in 2012, demonstrating the need for surveillance and rapid 
diagnosis of infections in returning travellers. 
This thesis aimed to seek the best possible practices in dengue and Zika 
diagnostics by studying and comparing the available methods of choice, 
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their combinations and different sample materials collected from Finnish 
traveller patients at different phases of the illness. Additionally, this thesis 
includes case studies exploring the molecular epidemiology of DENV and 
ZIKV and detailed characterization of a congenital ZIKV infection patient 
case. 
The detection kinetics of DENV NS1 antigen and RNA was studied from 
serum, urine and saliva samples. It was observed that NS1 antigen was 
detectable from the sera of travellers for notably longer periods than 
reported previously for populations living in endemic areas. A positive 
correlation between viremia at the time of sampling and the probability and 
duration of hospitalization were also noted, which is in line with previous 
observations in endemic populations. The association of viremia to a more 
severe disease outcome has also been observed in endemic populations. 
Importantly, urine and saliva were demonstrated to be potential sample 
materials for DENV diagnostics. Urine, in particular, provides new 
opportunities for molecular diagnostics of DENV as the time window for 
detection of viral RNA is notably later during the infection when compared 
to serum samples. From a patient case, it was observed that also ZIKV RNA 
detection was successful from urine whereas the serum sample taken at the 
same time point remained negative. Nowadays, urine is considered to be a 
suitable sample material in molecular diagnostics of flaviviruses, enabling 
detection of viral RNA beyond the early days of the infection. This also has 
significance for molecular epidemiological studies as the wider usage of 
urine samples as study material in flavivirus research has enabled obtaining 
more sequence data. 
Travellers play a role in spreading the viruses from one area to another, but 
also can serve as sentinels for studying their global circulation. By studying 
traveller patients, the DENV strain responsible for the Madeiran outbreak 
in 2012 was identified as DENV-1, most likely of South American origin. 
The characterization of a viral sequence from a Finnish traveller suspected 
of having DENV infection revealed the circulation of ZIKV in the Maldives 
for the first time. This case was followed by a few additional traveller cases 
identified elsewhere. Subsequently, the local authorities conducted 
surveillance studies and confirmed local transmission of ZIKV by detecting 
the virus from local mosquitoes. 
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A ZIKV patient case studied in this thesis was among the first reports to 
provide concrete evidence for the causality between ZIKV infection in a 
pregnant woman and malformations of central nervous system in the 
foetus. In this study the virus was isolated from the brain tissue of the 
foetus. The mother’s viremia was noticed to be prolonged, an observation 
that later studies have confirmed to be a common phenomenon in pregnant 
women infected with Zika virus. This case study demonstrated that the 
mother’s viremia was detectable weeks before the abnormalities in brain 
development were visible in ultrasound examinations. The evidence 
provided by the studies herein, along with other recently published data, 
have shown that there is a need to update the diagnostic guidelines.  
Although further studies are needed to examine the predictive value and 
possible use of a mother’s prolonged viremia in early detection of foetal 
infection, it seems like correctly timed screening of ZIKV RNA from a 
mother’s blood sample might enable detection of the infection in the foetus 





Denguevirukset 1-4 (DENV 1-4) kuuluvat hyttysvälitteisiin flaviviruksiin. 
Denguevirusten aiheuttamia infektioita diagnosoidaan yhä enenevässä 
määrin matkailijoilla, jotka vierailevat virukselle endeemisillä 
subtrooppisilla ja trooppisilla alueilla. Todennäköisiä syitä aiempaa 
korkeampaan ilmaantuvuuteen ovat kaukomatkailun ja epidemioiden 
yleistyminen sekä denguevirusten laajeneva maantieteellinen levinneisyys. 
Viime aikoina Suomessa on diagnosoitu noin 50–100 uutta tapausta 
vuosittain. Denguevirukselle sukua olevan hyttysvälitteisen zikaviruksen 
(ZIKV) ajateltiin aiemmin olevan varsin harmiton, Afrikassa ja Aasiassa 
satunnaisia lieväoireisia infektioita aiheuttanut virus. Vuodesta 2013 
lähtien zikavirus alkoi levitä nopeasti Polynesian kautta Etelä- ja Väli-
Amerikkaan sekä Karibialle, aiheuttaen näillä alueilla massiivisia 
epidemioita. Näiden epidemioiden yhteydessä zikavirusinfektioiden 
kliinisessä kuvassa havaittiin merkittäviä uusia tautiassosiaatioita. 
Zikavirusinfektio liitettiin vakaviin sikiön kehityshäiriöihin. Lisäksi myös 
aikuisilla potilailla esiintyi vakavia neurologisia oireita. 
Hyttysvälitteisten virusten levinneisyysalueiden laajeneminen on liitetty 
globalisaatioon sekä elinympäristöjen muutoksiin, kuten 
kaupungistumiseen ja ympäristön, mukaan lukien ilmaston muutokseen. 
Nämä muutokset ovat mahdollistaneet kahden tärkeän dengue- ja 
zikavirusta levittävän hyttyslajin, Aedes (Stegomyia) aegyptin ja Aedes 
(Stegomyia) albopictuksen leviämisen alueille, joilla näitä hyttysiä ei ole 
aiemmin esiintynyt. Erityisesti aasialaista alkuperää oleva Aedes albopictus 
leviää aggressiivisesti ja on nykyään endeeminen Etelä-Euroopassa sekä 
osassa Keski-Eurooppaa. Hollannissa on jo havaintoja tilapäisistä 
kasvihuonepopulaatioista, mikä korostaa näiden hyttyslajien 
pohjoisemmaksi leviämisen riskiä. Hyttysvälitteisen viruksen kotoperäinen 
leviäminen uudella alueella on mahdollista esimerkiksi kotiin palaavan 
matkailijan mukana. Tämä edellyttää, että alueella esiintyy virusvektoreiksi 
sopivia hyttyslajeja. Tällä vuosituhannella Eurooppa on jo kohdannut 
kotoperäisiä denguetapauksia Kroatiassa ja Ranskassa sekä merkittävän 
epidemian Portugalille kuuluvalla Madeiran saarella vuonna 2012. Tämä 
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korostaa kotiin palaavien matkailijoiden infektioiden pikaisen 
diagnostiikan ja toisaalta myös monitoroinnin tarvetta.  
Tämän väitöskirjatyön tavoitteina oli kehittää dengue- ja zikavirusten 
diagnostiikkaa tutkimalla ja vertaamalla sekä käytettävissä olevia 
diagnostisia menetelmiä ja niiden yhdistelmiä että erilaisia 
näytemateriaaleja. Työhön kerättiin näytteitä suomalaisilta matkailijoilta 
taudin eri vaiheissa. Väitöskirjatyössä tutkittiin myös potilastapauksia 
joiden flavivirusinfektioita tyypitettiin ja karakterisoitiin tiedon 
tuottamiseksi dengue- ja zikavirusten molekyyliepidemiologiasta.  
Väitöskirjatyössä tutkittiin denguevirusten NS1-antigeenin ja RNA-
osoituksen kinetiikkaa seerumista, virtsasta ja syljestä. NS1 antigeeni oli 
osoitettavissa matkailijoiden seeruminäytteissä huomattavasti pidempään 
kuin aiemmin oli raportoitu endeemisillä alueilla. Sairaalahoidon tarve ja 
kesto korreloivat positiivisesti näytteenottohetken viremian kanssa. Myös 
endeemisissä populaatioissa on huomattu yhteys viremian ja vakavampien 
tautimuotojen välillä. Virtsa ja sylki osoittautuivat potentiaalisiksi 
näytemateriaaleiksi denguevirusten diagnostiikassa. Erityisesti virtsa 
tarjoaa näytemateriaalina uusia mahdollisuuksia denguevirusten 
molekyylidiagnostiikkaan, sillä RNA-osoituksen aikaikkuna virtsasta 
sijoittui huomattavasti myöhempään sairaudenvaiheeseen kuin seerumista. 
Myös zikaviruksen osalta havaittiin, että zikaviruksen RNA osoitus 
virtsanäytteestä potilastapauksessa onnistui samanaikaisen 
seeruminäytteen jäädessä negatiiviseksi. Virtsan virus-RNA-osoitusta 
voidaan jo nyt käyttää potilasdiagnostiikkaan ja se soveltuu siihen myös 
taudin myöhäisemmässä vaiheessa. Tällä on merkitystä paitsi 
diagnostiikassa, myös molekyyliepidemiologisessa tutkimuksessa. 
Matkailijat voivat levittää viruksia uusille alueille, mutta mahdollistavat 
samalla kattavan näytemateriaalin virusten maailmanlaajuisen kiertokulun 
tutkimiselle. Matkailijanäytteiden avulla oli mahdollista osoittaa, että 
Madeiralla vuonna 2012 puhjenneen dengue-epidemian oli aiheuttanut 
DENV-1 virus, joka oli todennäköisesti peräisin Etelä-Amerikasta. 
Suomalaisella matkailijalla epäillyn dengueinfektion karakterisointi paljasti 
zikaviruksen esiintymisen Malediiveilla. Tämän potilastapauksen jälkeen 
diagnosoitiin myös muita matkailijatapauksia. Lisäksi paikalliset 
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viranomaiset ryhtyivät toimenpiteisiin, joiden tuloksena zikavirus 
osoitettiin myös paikallisista hyttysistä. 
Tähän väitöskirjatyöhön sisältyvä tutkimus oli ensimmäisten joukossa 
tuottamassa todistusaineistoa äidin zikavirusinfektion ja sikiön 
keskushermoston kehityshäiriöiden välillä. Tässä tutkimuksessa zikavirus 
eristettiin sikiön aivokudoksesta ensimmäistä kertaa. Lisäksi todettiin, että 
äidin viremia pitkittynyt ja oli havaittavissa useita viikkoja ennen kuin 
sikiön kehityshäiriöt olivat todettavissa kuvantamisella. Tutkimuksen 
havainto odottavan äidin pitkittyneestä viremiasta on vahvistunut 
myöhempien selvitysten myötä. Pitkittyneen viremian havaittiin olevan 
yleinen ilmiö raskaana olevilla, tartunnan saaneilla naisilla. Tämän 
väitöskirjatyön yhdessä muiden tutkimusten kanssa tuottama näyttö on jo 
vaikuttanut tämänhetkisiin diagnostisiin suosituksiin. Vaikka 
lisätutkimuksia vielä tarvitaan, on mahdollista, että oikein ajoitettu 
zikavirus-RNA:n seulonta äidin verestä voi mahdollistaa sikiön infektion 
havaitsemisen aikaisessa vaiheessa.  
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5. LITERATURE REVIEW 
 
5.1 Mosquito-borne viruses  
 
Mosquitoes act as vectors for a large variety of human and veterinary 
pathogens, including viruses. The mosquito-borne viruses (MBV) 
responsible for causing human diseases mainly belong to the virus families 
Flaviviridae, Togaviridae and Bunyaviridae, and occur worldwide. The 
most important MBVs, globally, include dengue 1-4 (DENV1-4), Zika 
(ZIKV), West Nile (WNV), Chikungunya (CHIKV) Yellow fever (YFV) and 
Japanese encephalitis (JEV) viruses 1,2. 
The genomes of these viruses are composed of RNA, which permits a faster 
rate of evolution than DNA, and therefore DNA viruses, due to the lower 
fidelity of RNA polymerase than DNA polymerase. Since mutations in a 
virus genome may lead to changes in features of the virus, for example its 
pathogenesis or mode of transmission, this may in turn lead to serious 
outbreaks of a virus or the expansion of a virus’ distribution. In spite of this, 
the necessity for MBVs to survive in two very different hosts (arthropods 
and vertebrates) is proposed to result in a restricted mutation rate 
compared to other human pathogenic RNA viruses 3,4. 
 
5.1.1 Mosquito-borne flaviviruses 
 
The family Flaviviridae consists of three genera: Flavivirus, Pestivirus and 
Hepacivirus. This thesis focuses on mosquito-borne members of genus 
Flavivirus (in this thesis term Flavivirus refers to genus), which includes 
mainly arthropod-borne viruses (arboviruses) that mainly infect, and are 




Figure 1. Maximum likelihood (ML) phylogeny based on NS-5 gene sequences from 70 
viruses of the genus Flavivirus. Dengue and Zika viruses are highlighted. Modified from 
Infection, Genetics and Evolution, Vol 3, Holmes EC & Twiddy SS, The origin, emergence 
and evolutionary genetics of dengue virus, Pages 19-28 No. 1, Copyright (2017), with 
permission from Elsevier.  
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Of the 71 species of Flavivirus currently reported, 38 species are confirmed 
to be mosquito-borne, 19 are tick-borne and 16 have no known vector 
(Figure 1.). Tick-borne viruses compose only one serocomplex and are all 
closely related, whereas mosquito-borne flaviviruses comprise seven groups 
(Figure 1.)5. Many mosquito-borne and tick-borne flaviviruses are globally 
important human pathogens, such as YFV, JEV, ZIKV, dengue, and tick-
borne encephalitis (TBEV), whereas some have no known association to 
human disease. A summary of human pathogenic mosquito-borne 
flaviviruses is shown in Table 1. 1,6,7. 
 
Table 1. Human pathogenic mosquito-borne flaviviruses, the year of isolation, distribution area, host 
if known, vector and disease association. 
 
 
The type species within the genus Flavivirus is yellow fever virus (YFV), 
which originated in Africa about 1500 years ago and spread 300-400 years 
ago by slave trade to South and Central America but not to Asia. YFV spread 
rapidly in South America and has now been established to circulate in 
sylvatic cycle between mosquitoes and non-human primates 8. The main 
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urban vector of YFV is Ae. aegypti, a very important vector species for 
several flaviviruses, but other mosquito vectors include species in genus 
Aedes and there are sporadic reports of YFV virus from other mosquito 
genera and even Amblyomma ticks 9,10. Symptoms of YFV infection include 
self-limiting febrile disease but the severe infection that develops to 
approximately 15% of patients, is characterized with hemorrhages, jaundice 
and abdominal pain. Severe form is fatal in around 50% of cases 10-13. 
Mosquito-borne flaviviruses are phylogenetically divided into seven groups 
(Figure 1.): Aroa virus group, Japanese encephalitis group, Ntaya virus 
group , Kokobera virus group, dengue virus group, Spondweni virus group 
with Yellow fever virus group 5. 
 
5.1.2 Mosquito-borne flaviviruses in Europe 
 
WNV is endemic in parts of Southern, Central and Eastern Europe 14-20. 
Usutu virus (USUV) has also been reported from South and Central Europe, 
from mosquitoes and non-human vertebrates in addition to human cases 20-
30. Both WNV and USUV are MBVs that originated in Africa and are 
transmitted by Culex mosquitoes, and thus have different life cycles to 
dengue and Zika due to their preference for different vertebrate hosts 
(birds). Of these, WNV has more importance as a human pathogen and is 
associated with encephalitis, whereas USUV is considered more as an 
infection of birds24,31,32. Several flaviviruses with no known disease 
associations have been identified from mosquitoes in Europe. Finnish 
viruses without disease associations include Lammi (LAMV) and Ilomantsi 
(ILOV) viruses, genetically associated with human pathogenic flaviviruses 
33,34 and Hanko (HANKV) virus grouping with insect-specific flaviviruses 34-
36. Even though LAMV and ILOV have not been shown to replicate in 
certain vertebrate cell lines (including cell lines from monkeys, hamster, 
canine and human) or in newborn mice that usually are susceptible for 
MBV infections to date, it remains unclear whether they are able to infect 
some vertebrate species in vivo 33,34. 
19 
 
Dengue viruses have caused several autochthonous, self-limited, outbreaks 
in Europe. In Greece, the most serious outbreak occurred in the 1920’s 
when over a million cases occurred, and resulted in around 1500 deaths. 
Prior to this, Greece had also had several, smaller, outbreaks in the late 
1800s and early 1900s 37,38. After decades without any autochthonous cases, 
outbreaks with just few cases in France (in Nice) and Croatia took place in 
the 2000s 39-41. Shortly after, in 2012, a large outbreak with 1080 confirmed 
cases took place on the Portuguese island of Madeira, though no severe 
complications or fatalities were reported. 42-44. Between 2013 and 2015 there 
were sporadic outbreaks with a few cases in France. For most of the 
outbreaks outlined above, DENV-1 was the serotype responsible for the 
human cases, although the sequence data from the French case caused by 
DENV-2 is lacking. The vector mosquito was Ae. aegypti in at least the 
Greek and Madeiran outbreaks 37,43,45 and Ae. albopictus in France 39. These 
European outbreaks most likely result from the expansion of the dengue 
vectors distribution, and therefore the virus distribution into Europe from 
Asia, increase of travelling to dengue endemic areas and an overall increase 
in air traffic and therefore human mobility.  
 
5.1.3 Other mosquito-borne viruses 
 
Other mosquito-borne viruses with medical importance include 
alphaviruses, orthobunyaviruses and members of Reoviridae. These viruses 
are partly present in the same areas as DENV and ZIKV, and symptoms 
often overlap, making these viruses important for differential diagnostics. 
The genus Alphavirus in family Togaviridae includes many medically 
important mosquito-borne viruses, which have single-stranded positive 
sense RNA genomes 46. The most important human pathogen of this genus, 
globally, is arguably CHIKV, which is transmitted by several species of 
Aedes mosquitoes. Symptoms of infection reflect those of DENV and ZIKV 
but severe and often chronic arthalgias are more descriptive of CHIKV 
infection than DENV and ZIKV. In contrast to these flaviviruses, most of the 
CHIKV infections are symptomatic 47. Though the first reports of CHIKV 
epidemics were made from Tanzania in 1953, it wasn’t until after 2004 that 
it became a widespread problem when a new epidemic strain emerged. This 
new strain first spread into Asia and Africa, then in 2013 was reported in 
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the Western hemisphere, later causing outbreaks in Europe 48,49. Human 
cases of DENV, ZIKV and CHIKV are transmitted by the same two 
mosquito species, Ae. Aegypti and Ae. albopictus, therefore their 
geographical distributions overlap. 50,51. In Finland, Sindbis virus (SINV) is 
transmitted by Culex mosquitoes. Sindbis causes a disease in humans with 
fever, rash and prolonged arthalgias 52. Despite viruses of which clinical 
picture is characterized by arthritis, there are alphaviruses causing 
encephalitis namely western- (WEEV), eastern- (EEEV), Venezuelan 
(VEEV) equine encephalitis viruses are transmitted by several mosquito 
species. These viruses are often referred to as New World viruses as their 
distribution area is the Americas 53. 
Most virus species in Bunyaviridae infect animals, being either arthropod- 
or rodent-borne viruses and have segmented, negative sense RNA genomes 
54,55. The genus Orthobunyavirus includes many mosquito-borne viruses, 
including La Crosse, Oropouche and Ngari viruses. The clinical picture of 
human pathogenic orthobunyaviruses varies and the outcomes include, in 
addition to self-limiting febrile illness, encephalitis and haemorrhagic fever. 
Orthobunyaviruses are also important veterinary pathogens, which notably 
include Schmallenberg virus, which recently spread to Europe 56,57. In 
Finland, seroprevalence against Inkoo (INKV) and Chatanga (CHATV) 
viruses is high. These mosquito-borne orthobunyaviruses are known usually 
to cause mild self-limiting disease but both are occasionally associated with 
neurological complications 58. 
 
5.2 DENV and ZIKV: phylogeny and epidemiology 
 
DENV and ZIKV share antigenic similarity despite belonging to different 
groups (dengue virus group and Spondweni virus groups, respectively). The 
amino acid sequence of the E gene, the main target of neutralizing 
antibodies, shares 54-59% similarity between the dengue virus group and 
ZIKV 59.  
Dengue viruses are classified into four serotypes (1‒4) that are genetically 
related but antigenically distinct from each other, sharing 60‒70% sequence 
identity 3,60. They were first isolated from Japan and Hawaii during the 
Second World War in 1943 and 1945, despite the fact that the disease had 
been known for centuries 61. The Hawaiian virus was designated as DENV-1 
and subsequently it was noted that Japanese virus also represented DENV-
1. DENV-2 was first isolated from New Guinea 61 while DENV-3 and DENV-
4 were later isolated following an outbreak of Dengue in the Philippines in 
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1956 62. All further dengue viruses subsequently fitted into one of these four 
serotypes until 2013 when a possible fifth serotype was reported. This ‘new’ 
serotype was reported to have been isolated from a sample taken from a 
farmer from Malaysia, Sarawak in 2007 but at the time of writing this thesis 
no sequence data has been provided to support this claim 63,64. All serotypes 
are further classified into genotypes, which share about 92‒96% sequence 
similarity at the nucleotide level, based on their phylogenetic relationships. 
Genotypes are generally associated with different geographical distributions 
and they vary in their abilities to cause severe disease 3,65,66. 
DENV-1 is classified into five genotypes based on the E gene, or on 
complete genome sequences 65,67-70. In addition to genotypes representing 
epidemic strains, the classification includes the sylvatic genotype, which is 
represented by two strains originating from Malaysia. The sylvatic origin of 
these strains has, however, been questioned and it has been suggested that 
they are possibly spillbacks from humans to monkeys 71,72. Genotype II 
comprises old strains (1950-1960s) from Thailand. These strains have not 
been reported since the 1960s but they may still circulate with low 
frequency. Asian genotype I consist of strains from across Asia and has 
caused numerous outbreaks in the area in the 2000s. Genotype IV, or the 
South Pacific genotype, comprises strains from the West Pacific and 
Australia. Genotype V represents all strains from the Americas, in addition 
to African and some Asian strains, and is designated as the 
American/African genotype 65,67-70. 
Based on E gene sequences DENV-2 is classified into five genotypes; two 
Asian, a Cosmopolitan, an American and an American/ Asian genotype, of 
which one represents sylvatic strains from West Africa and South East Asia, 
and four represent epidemic strains. The Asian genotype is divided into 
two: Asian genotype I, comprising strains from Malaysia and Thailand; and 
Asian genotype II with strains from Vietnam, China, Taiwan, Sri Lanka and 
the Philippines. The Cosmopolitan genotype consists of strains with a wide 
geographical distribution from Pacific and Indian Ocean islands, to the 
subcontinent of India, Australia, Africa and the Middle East. The American 
genotype includes, in addition to strains from the Americas until the 1980s, 
older strains from Pacific islands, the Indian subcontinent and Caribbean 
area (collected in the 1950s and 1960s). The American/Asian genotype 
spread from Asia to the Americas in the 1980s and comprises the American 
strains from the last few decades in addition to strains from Thailand and 
Vietnam. Introduction of American/Asian genotype to Americas and the 
replacement of the American genotype by it were followed by DHF 
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outbreaks in Americas. American/Asian genotype has been linked to more 
severe disease. 65,73-75. 
Classification of DENV-3 into four genotypes is based both on complete 
genome sequences and on sequences of the prM/E region 76,77. Genotype I 
consist of Asian strains (from Indonesia, Malaysia and the Philippines) and 
strains from islands of the South Pacific. Genotype II comprises Asian 
strains similar to genotype I but which originate from Thailand, Vietnam 
and Bangladesh. Genotype III includes strains from Asia (Sri Lanka, India), 
Africa and Polynesia (Samoa). Genotype IV consists of the American strains 
and strains from Tahiti 76,77. 
DENV-4 is classified into four genotypes based on the E gene, and complete 
genome sequences 78,79. Of these, one represents sylvatic strains from 
Malaysia (genotype IV) and three represent epidemic strains. Genotype I 
represents Asian strains (Thailand, Sri Lanka, Japan and Philippines) 
whereas genotype II consists of American and Caribbean strains in addition 
to Asian (Indonesia and Malaysia) strains. Genotype III includes recent 
strains from Thailand 79. 
DENV is distributed worldwide across the tropics and subtropics, in mainly 
urban and semi-urban environments. While many areas have varying 
numbers of serotypes present at any one time, some areas, e.g. South East 
Asia and Brazil, are hyperendemic for dengue 80,81. A region is considered 
hyperendemic when all four serotypes circulate simultaneously.  
It has been estimated that 390 million people become infected with dengue 
annually, and of these approximately 96 million cases are symptomatic. Of 
all clinical DENV infections approximately 70% occur in Asia 82, but the 
DENV endemic areas and also the global incidence of DENV have rapidly 
increased in recent years. The two primary factors behind the expansion of 
the distribution of dengue are considered to be the introduction of the 
vector mosquitoes into previously uncolonised areas, which is considered to 
be the only limiting factor of establishment of dengue, and the importation 
of viruses via viremic travellers 43,83-86. Urbanization has also had a great 
impact on the increase and expansion of dengue. The artificially dense 
human populations in urban areas create a multitude of microhabitats, 
which can act as mosquito breeding sites. Vector mosquito species take full 
advantage of these sites, and dense mosquito populations can thrive. When 
23 
 
dense populations of both humans and mosquitoes inhabit the same 
environment, the possibility for disease transmission is substantially 
increased 87. The two primary vectors of DENV and ZIKV, Ae. aegypti and 
Ae. albopictus, are both able to inhabit these urban environments, and 
therefore can cause high disease burdens in some areas. Dengue is currently 
considered to be the most important mosquito-borne viral disease, globally, 
from economic and public health perspectives 82,88. In 2013 Shepard et al 
estimated the annual global burden of dengue to be 8.89 billion US$. This 
figure takes into account hospitalised and ambulatory non-fatal cases, non-
fatal non-medical cases and fatal cases, of which the hospitalised non-fatal 
cases accounted for 46% of the total cost. They also observed that the costs 
of dengue exceed costs incurred by other infectious diseases with 
comparable data 88,89. 
Zika virus was first discovered from Ziika forest, Uganda, where it was 
isolated from a sentinel monkey in 1947 and from Ae. africanus mosquitoes 
(a forest canopy species) collected from the same area in the early 1960s 
90,91. The first human cases of ZIKV were recognised in Nigeria in the 1950s 
by observing neutralizing antibodies against ZIKV, and one case by viral 
isolation during an outbreak of jaundice that was mistakenly thought to be 
caused by YFV 92,93. Only sporadic human cases (n=13) were recorded from 
Africa and South-East Asia from the 1950s until 2007 (Figure 3), when a 
major outbreak from Yap Island, Micronesia, was reported. In this 
outbreak, a third of Yap residents were infected with ZIKV. Considering the 
incidence of the cases prior to the outbreak, the number of infections was 
unprecedented 94. Zika then spread to French Polynesia, where it caused 
outbreak with approximately 32 000 cases in 2013‒2014 95,96. In 2015 the 
first reports of ZIKV in the Americas were made from Brazil, after which it 
rapidly swept across South and Central America and the Caribbean area 97. 
To date, ZIKV is distributed across sub-Saharan Africa, South-East Asia, 




Figure 2. The distribution of ZIKV. Areas coloured blue represent areas with ZIKV cases 
prior to 2007 and red areas are where Zika emerged after 2007. From Huhtamo E, 
Jääskeläinen AJ, Sane J, Nohynek H, Vapalahti O.: Zikavirus. Duodecim 2016;132:1521–9. 
Reprinted with permission from Aikakauskirja Duodecim. 
 
Phylogenetically, ZIKV shows most homology with Spondweni virus 
(SPOV). Phylogenetic analyses show that there are two lineages of ZIKV; 
the African lineage and the epidemic Asian lineage. The African lineage has 
further been classified into West and East African (which includes the 
prototype MR766 strain from Uganda) lineages 99,100. Combining the 
epidemiological data with the phylogeny of ZIKV it has been estimated that 
the Asian lineage underwent genetic change, which resulted in the epidemic 
strain with higher virulence 100-102. The complications associated with ZIKV 
infection (e.g. microcephaly and Guillain-Barre syndrome) were not 
observed until the French Polynesian outbreak. Prior to the 2007 Yap 
Island outbreak, fewer than 20 human cases had been reported in several 
decades 101. 
5.3 Coding strategy, replication and structure of flaviviruses 
 
Flaviviruses are enveloped, positive sense single-stranded RNA viruses, and 
their genome functions as messenger RNA in a host cell. The virus particles 
are spherical, with a diameter around 50nm. Genome size varies between 
25 
 
species, but is approximately 11 kb; DENV serotypes vary between 10.6 to 11 
kb 103 and ZIKV is 10.7 kb 104. 
Flaviviruses utilise receptor-mediated endocytosis in a clathrin-dependent 
manner to enter host cells. E protein of the virus interacts with the receptor 
of the host cell’s plasma membrane. Dengue virus uses several different 
receptors for the internalisation, which include glycosaminoglycans, the 
mannose receptor (MR) of macrophages, the adhesion molecule of 
dendritic cells (DC-SIGN) and stress-induced proteins 105-107. Once in a cell, 
the virion fuses with the endosomal membrane, triggered by acidification of 
the late endosome, which enables the release of RNA into the cytosol 
(Figure 3.) 105,108. After initial translation of the genome, the replication 
complex is formed in the perinuclear endoplasmic reticulum (ER) followed 
by RNA replication and protein translation (Figure 3.). Flaviviruses’ 
genomes code for ten proteins; three structural and seven non-structural 
proteins (Figure 4.). These are translated in the cytoplasm as one large 
polypeptide and then cleaved post-translationally into single proteins by 
proteases of both the virus and the host 109,110. Newly synthesised positive-
sense RNA is packed into the capsid protein and assembled into an 
enveloped virion, formed by prM/E heterodimers. The maturation of the 
virions occurs in the Golgi apparatus by cleavage of prM protein by furin 
protease. Partially or fully mature virions are finally secreted out of the cell 





Figure 3. Replication cycle of flaviviruses in mammalian cells. Reprinted by permission 
from Macmillan Publishers Ltd: Nature Reviews Microbiology, Mukhopadhyay, S et al, A 
structural perspective of the flavivirus life cycle, copyright (2005). 
 
Figure 4. Flavivirus genome organization. Reprinted by permission from Macmillan 
Publishers Ltd: Nature Reviews Microbiology, Guzman MG et al, Dengue: A continuing 
global threat, copyright (2010).  
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The three structural proteins, capsid (C), membrane (M) and envelope (E) 
are components of a flavivirus virion. The capsid protein forms the 
icosahedral capsid (Figure 5.), while the M and E proteins are displayed on 
the surface of the virion. The M protein is first synthesised as prM, which is 
then cleaved by furin into to an M protein and a pr peptide as the virion is 
secreted from the cell (Figure 5.). The E protein interacts with cellular 
receptors and is considered to be the main target of neutralizing antibodies 
112,113. 
The seven non-structural (NS) proteins, designated as NS1, NS2A and 
NS2B, NS3, NS4A and NS4B and Ns5, are present in the infected cells 103. 
The role of these NS proteins is at present only partially understood but 
they are known to mediate virus replication, interplay with host cell and 
have associations to pathogenic properties of the virus 114. The open reading 
frame is flanked with 5’ and 3’ untranslated regions (UTR). The promoter 
region of viral RNA lies within the 5’ UTR region and these regions include 
secondary structures that are necessary for replication, translation and 
pathogenesis in vertebrate cells 103,115,116. 
 
Figure 5. Structure of immature and mature flavivirus particle (Yellow fever). A. A cross-
section of the virion showing both an immature (left) and mature (right) virion. Mature 
particles are formed after cleavage of prM. B. Arrangement of E dimers at the surface of 
mature dengue 2 virion. Adopted and modified from Vratskikh O et al:. Dissection of 
antibody specificities induced by yellow fever vaccination. PLoS Pathog. 2013;9(6). 




The NS1 protein has many functions in flavivirus infections. These 
functions have been studied with different flaviviruses and they might not 
be the same in all flaviviruses. Both the secreted and membrane-bound 
forms have been shown to elicit an immune response, while the 
intracellular NS1 plays a crucial role in viral replication. NS1 is represented 
in three forms; monomeric, dimeric and hexameric. Secreted (hexameric) 
and membrane-bound (dimeric) forms of the NS1 antigen can interact with 
the complement components and activate the complement system and thus 
elicit complement-dependent cytotoxicity in endothelial cells. This might 
also play a role in antigen dependent enhancement of the DENV infection. 
117-121. Additionally, the NS1 protein has complement inhibiting activity 121. 
The NS1 protein has been demonstrated to activate Toll-like receptor 4 
(TLR4), which leads to cytokine production and leakage of endothelial cell 
monolayer, in DENV infections. It has also been demonstrated that there is 
an association between high NS1 levels in a host’s circulation and the 
enhancement of mosquito infectivity of ZIKV. The cytokines induced by NS1 
might significantly contribute to the vascular leakage in severe dengue 122,123. 
The extended form of NS1, NS1’, is reported in some flaviviruses, namely 
JEV serogroup and WNV. This extension is produced as a result of -1 
ribosomal frameshifting and has been associated with neuroinvasiveness of 
the virus 120,124-126. 
The relatively smaller non-structural proteins NS2A, NS2B, NS4A and 
NS4B are all hydrophobic and are thus identified as membrane-associated 
proteins 103. They have not been shown to possess enzymatic activity and are 
therefore considered to function via protein-protein or protein-lipid 
interactions 114. NS2A plays a role in the processing of NS1 127, while NS2B is 
part of a protease complex with NS3 128.  
Among flaviviruses, NS3 and, in particular, NS5 are highly conserved 
proteins. NS3 has helicase and protease activity, while NS5 plays a role as 
an RNA-dependent RNA polymerase and is also involved in capping viral 
RNA 114,129. NS5 has additionally been shown to play a role in evading the 
host’s immune response by downregulating the interferon response in 





5.4 Transmission of dengue and Zika viruses 
 
As dengue and Zika viruses are mosquito-borne, their lifecycles include 
replication in both mosquito and mammalian hosts. They share similar 
transmission cycles that include the urban cycle between humans and 
Aedes1 mosquitoes (Diptera: Culicidae), mainly Ae. aegypti and Ae. 
albopictus, (Figure 6.) which differs from e.g. JE serogroup MB viruses that 
require a wild vertebrate (birds) amplifying host for maintaining the life 
cycle, and a sylvatic cycle in the jungle between mosquitoes and non-human 
primates (Figure 7). Many mosquitoes from the large and cosmopolitan 
genera Aedes and Culex can act as vectors for flaviviruses. Viruses 
transmitted by Aedes mosquitoes frequently have transmission cycles 
between non-human primates and cause hemorrhagic fevers in humans, 
like DENVs and YFV. In contrast, viruses transmitted by Culex mosquitoes 
typically are transmitted between birds and cause encephalitis-like WNV 
and JEV when human infection occurs 1. 
A  B 
Figure 6. The primary vector species of DENV and ZIKV. A. Ae. (Stg.) albopictus, and B. 
Ae. (Stg.) aegypti. Photographs courtesy of Anders Lindström, SVA. 
 
The sylvatic dengue cycle, between mosquitoes and primates in the jungle 
(Figure 7.), is well studied. Sylvatic cycles of DENV-2 have been shown to 
occur in West Africa, Senegal, 131-133 South East Asia, in peninsular Malaysia, 
                                                             
1 This thesis follows the mosquito classification of Wilkerson, et al (2015) rather than the earlier 




whereas sylvatic cycles of DENV-1 and DENV-4 have been recorded only 
from South East Asia 66,74,134. Sylvatic strains of DENV-3 have not been 
isolated to date, but serological data indicate that sylvatic DENV-3 also 
circulates between primates in the Malaysian jungle of South East Asia 66. 
Sylvatic cycles of DENV in the Americas has not as yet been proven but 
serological data from members of an indigenous Indian tribe in Bolivia 
living in a restricted area with no presence of Ae. aegypti, may suggest that 
sylvatic transmission of dengue is possible 72,135. The mosquitoes 
transmitting the virus between non-human primates in sylvatic dengue 
cycles are arboreal species, in Africa Ae. (Stg.) luteocephalus and Ae. (Dic.) 
furcifer and in South East Asia Ae. (Dow.) niveus 3 and the main reservoirs 
in Africa include the Patas monkey (Erythrocebus patas), African green 
monkey (Chlorocebus sabaeus) and Guinea baboon (Papio papio), whereas 
in Asia the primary hosts of sylvatic cycle seem to be cynomolgus macaques 
(Macaca fascicularis), Southern pig-tailed macaques (Macaca nemestrina) 
and silvered leaf monkeys (Presbytis cristata) 3. 
The sylvatic cycle of ZIKV has been documented in West Africa with 
isolations from non-human primates and the sylvatic Aedes mosquitoes 
collected from the forest canopy and floor 136,137. Serosurveys have also 
recovered antibodies against ZIKV in African non-human primates 138. To 
date there is no evidence of an Asian ZIKV sylvatic life cycle, but it cannot 
be excluded as the surveillance of arboviruses in Asia is not comprehensive 
137. 
The main vector in urban life cycle of DENV and ZIKV is Ae. aegypti. 
Dengue viruses are also transmitted by Ae. albopictus, which has only 
recently been shown to be susceptible for ZIKV replication. ZIKV has been 
found in the saliva of Ae. albopictus experimentally infected with the virus 
139 and ZIKV RNA was detected in similar proportions as DENV RNA from 
Ae. albopictus during the 2007 DENV outbreak in Gabon 140. Even though 
Ae. aegypti and Ae. albopictus are established vectors of Zika virus, 
Chouin-Carneiro et al. demonstrated that the vector competence of both 
species for the Asian genotype of the virus was lower than expected. Among 
the mosquitoes tested, a low proportion were able to transmit Zika virus yet 
the transmission rates of the mosquito populations from different 
geographical regions varied 141. ZIKV RNA has also been detected from 
other Aedes species and some of these have been found susceptible for 
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ZIKV; the role of these species in ZIKV transmission remains to be studied 
94,142. Yet there is cumulating evidence for the vector-competence of Cx. 
quinqefasciatus for ZIKV, other Cx. species have not been demonstrated to 
be able to transmit ZIKV 94,143,144. 
 
Figure 7. Sylvatic and urban transmission cycles of DENV. From Chen R & Vasilakis N: 
Dengue--quo tu et quo vadis?. Viruses 2011 Sep;3(9):1562-608. Reprinted with permission 
from MDPI. 
 
In addition to vector-borne transmission, Zika virus is efficiently 
transmitted both prenatally and sexually. This feature is remarkable within 
genus Flavivirus as the main transmission routes of these viruses are via 
arthropod vectors. Even though cases of vertical transmission of DENV 
from mother to neonate have been reported, these reports have been 
incidental 145-148. If a mother is infected with ZIKV then the foetus is 
predisposed to contract the infection. The risk of prenatal transmission and 
the complications of infection for the foetus seem to be greatest during the 
first trimester, though both transmission and foetal damage can occur 
during any trimester 149-151. In addition to prenatal transmission, Besnard et 
32 
 
al (2014) reported perinatal transmission of ZIKV prior to current outbreak 
152. Prenatal and sexual transmission make ZIKV extraordinary in the genus 
Flavivirus as none of the other members are known to be transmitted via 
these routes with same efficiency and significance. Another remarkable 
feature is the prolonged excretion of ZIKV to semen in infected males up to 
six months post-infection suggesting persistent infection 153-156.  
When the virus is prenatally transmitted from mother to foetus a persistent 
infection may also occur in the foetus 157,158. Although transmission via 
breastfeeding has not yet been reported, ZIKV has nonetheless been 
detected from breast milk 159,160. The experiments with rhesus macaques 
showed low infectivity of ZIKV of oral secretions, yet there is a risk of 
mucosal route of transmission 161. Transmission has also been demonstrated 
via blood transfusions 162-164, and via monkey bites or laboratory infections 
165-167. Reports for other flaviviruses describe other, rare, routes of 
transmission, such as blood transfusions, needle-stick injuries and organ 
transplants 168-173. WNV is known to be transmitted via blood transfusions 
and blood donors have been screened for WNV in United States since 2003 
171,174 TBEV, a tick-borne flavivirus, is known to be transmitted via 
unpasteurised goat milk and to have caused occasional milk-borne 
outbreaks 175-177. In addition, transmission via blood transfusion has been 
reported for TBEV 178. 
 
5.5 Clinical manifestations and pathogenesis of DENV and ZIKV infections  
 
The clinical manifestations of acute DENV and ZIKV infections, including 
fever, rash, myalgias, resemble one another as well as CHIKV infection. For 
DENV and ZIKV infections the clinical picture varies from asymptomatic 
infection to serious and even life-threatening complications. Despite many 
similarities in the clinical pictures, the severe manifestations of DENV and 
ZIKV infections are different. In ZIKV infection, the severe complications 
are associated with neurological symptoms (brain abnormalities in foetuses 
and Guillain-Barre syndrome in adults), whereas the hallmark of severe 
dengue infection is characterized with plasma leakage due to increased 
vascular permeability leading possibly to hypovolemic shock. 
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Dengue infection is often asymptomatic or exhibits symptoms resembling a 
mild, flu-like disease. The classical form of dengue infection, dengue fever, 
originally termed breakbone fever, is characterized by fever, rash, headache 
and severe muscle pain (Table 2) 179,180. The incubation period of DENV 
infection varies from 3‒10 days and the viremic phase often sets in before 
symptoms occur 181. Severe complications of dengue infection include 
plasma leakage, hemorrhages and organ impairment (Table 2). This 
condition is classified as severe dengue by the WHO (former classified in 
dengue hemorrhagic fever, DHF, and dengue shock syndrome, DSS) and it 
may be fatal. The critical point is defeverscence 3‒7 days after onset of 
initial symptoms. Warning signs to severe dengue include severe abdominal 
pain, persistent vomiting, hematemesis, rapid breathing, bleeding gums, 
fatigue and restlessness. It has been estimated that 1‒2% of human 
infections develop into the severe forms with fatality rate of 5%. Fatal cases 
are often caused by shock due to plasma leakage and subsequent 
hypovolemia (Table 2.). Maintenance of the patient’s body fluid volume is 
thus essential in treatment of severe dengue 180,182. 
Table 2. Clinical manifestations of different forms of DENV infections. The classification 
according to WHO 180. 
 
The mechanisms underlying severe dengue are complicated and still the 
subject of research. Many immunopathogenetic mechanisms have been 
identified underlying behind severe dengue symptoms. Non-neutralizing, 
infection-enhancing antibodies promote the intake of the viruses by 
phagocytic cells like dendritic cells and macrophages through Fc-receptors 
leading to enhanced infection of these cells. Plasma leakage is thought to be 
mediated by the TLR-4 activated cytokine storm and NS1 triggered 
complement system. Chymases, mediators produced by mast cells, have 
also been associated with increase in vascular permeability during severe 
dengue infection 59,183. 
34 
 
Infection by one serotype of DENV gives a lifelong immunity against 
subsequent infections by that serotype but only short-term (2‒3 months) 
immunity against the other serotypes 184. Previous infection with another 
serotype of DENV is actually considered to predispose the patient to a more 
severe infection via antigen dependent enhancement (ADE) 185-188. In this 
phenomenon, existing but non-neutralizing antibodies invigorate the 
secondary infection by enhancing the uptake of DENV to cells with Fc 
receptors (monocytes, macrophages), which display the major replication 
site of DENV in vivo 188,189. It has been suggested based on functional studies 
that immature DENV particles are non-infectious, yet antibodies against 
prM (the uncleaved M protein, present in immature virus particles) are 
shown to enhance the infection. However, it was shown that in the presence 
of prM antibodies, primarily in secondary infections, immature virus 
particles became as infectious as mature virion. Subsequently, study by 
Richter et al showed the ability of immature DENV particles to infect 
immature human dendritic cells via DC-SIGN molecule in primary 
infections. 189-191. Children born to mothers with prior exposure to DENV, 
who are themselves later exposed to the virus, are at risk while they still 
carry maternal antibodies during their first few months 192. Even though the 
severe forms of dengue are often associated with secondary infections, they 
can occur also in primary infections. In Finland one case of lethal primary 
dengue infection has been reported 193.  
Pathogenesis of DENV infections is not yet fully understood, yet it is known 
that properties of both the virus and the host have an effect in the outcome 
of the infection. Some of the sero- and especially genotypes of the viruses 
are more often associated with the severe forms of the infection than others 
194-198. Host-dependent factors associated with higher risk for severe dengue 
include being young, female, having a high body-mass index and the host’s 
genetics 199-201. As described above, secondary infection is known to be a 
predisposing factor for severe forms of dengue. Yet, no associations of 
tertiary infections and severe dengue have been observed and it has been 
suggested that antibodies produced due to secondary infection would 
provide neutralizing protection even to serotypes other than the initial 
infecting strain 112. The scene between endemic countries and travellers 
from non-endemic areas differs greatly: in endemic areas primary cases are 
mostly seen in children while adults have secondary infections; whereas 
35 
 
within travellers the patients are usually adults who develop primary 
infection.  
Zika virus infection, until recently, was considered to resemble a mild 
version of DENV. The symptoms are often very similar in both infections 
but with notable differences: plasma leakage in severe cases is not 
characteristic for ZIKV infection, whereas conjunctivitis is typical for Zika 
rather than dengue. Up to 80% of ZIKV infections are asymptomatic and 
usually the possible symptoms are quite mild and the disease self-limiting 
with symptoms like fever, rash, conjunctivitis and arthalgias. In 2015, 
during the epidemic in South America, the number of cases of foetal 
microcephaly increased by 20-fold. This quickly raised questions of a 
possible association between maternal ZIKV infection and foetal 
microcephaly, with rapid investigations confirming the association 
149,150,202,203. Later, it was discovered that the microcephaly cases are just part 
of the myriad of foetal developmental disorders caused by Zika, jointly 
called Zika congenital syndrome. Complications of foetal ZIKV infection 
include spontaneous abortion, stillbirth, hydranencephaly and other 
neurological, ophthalmologic, and auditory manifestations in addition to 
microcephaly 150,151,157,204-211. Abnormalities in the placenta, umbilical cord 
and amniotic fluid have also been reported in pregnant women with ZIKV 
infections 149,151. Subsequent studies have observed microcephaly and other 
neural abnormalities in the epidemics of French Polynesia between 2013‒
2014 212,213. 
In addition to foetal abnormalities, ZIKV also causes neurological 
symptoms in adults. An increase in the number of cases of Guillain-Barré 
syndrome (GBS) occurred during the outbreak in French Polynesia in 2013 
214,215 and 2015 in South America 216-218. Guillain-Barré syndrome is a 
disorder in which the immune system targets parts of the peripheral 
nervous system and symptoms include weakness or tingling sensations in 
the legs progressing towards the upper body. In the severe form of the 
syndrome the patient becomes almost totally paralyzed and the condition 
can be life threatening. In most cases, a spontaneous recovery occurs, but 
some patients may develop chronic manifestations. Data based on French 
Polynesia outbreak suggest a risk of GBS at a rate of 2.4 per 10 000 ZIKV 
infections 219. In GBS cases due to ZIKV infection, symptoms have been 
observed to manifest already during or immediately after the acute 
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infection which is atypical for GBS related to infections in general and 
prolonged viruria has been associated with this complication 217. 
Other severe neurological manifestations associated with ZIKV infections 
are rare and mostly associated with other, chronic, health disorders. Cases 
with meningoencephalitis, encephalopathy and myelitis have been reported 
sporadically 220,221. Sporadic lethal ZIKV cases have been reported amongst 
adults but these are associated with co-morbidities 221,222. 
DENV and ZIKV can cause co-infections 223. This may be especially 
significant since existing non-neutralizing antibodies against DENV have 
been shown to enhance ZIKV infection by promoting ADE and a correlation 
between ZIKV related GBS and previous DENV infection has been observed 
187,217,224. This suggests that prior dengue infections might predispose to more 
severe outcome in subsequential ZIKV infection, yet the most recent studies 
show controversial results 225,226. This still is a phenomenon to be considered 
when developing vaccines against these diseases. The true significance of 
this phenomenon is currently unknown, but given the subject further 
research is expected during the next few years. 
 
5.6 Laboratory diagnostics of DENV and ZIKV infections 
 
As the symptoms of infections caused by ZIKV or DENV resemble each 
other and these viruses co-circulate in several geographical regions, these 
infections cannot be distinguished on the basis of the clinical picture of the 
disease. Clinical manifestations of other febrile vector-borne diseases, 
particularly CHIKV or malaria, may likewise, resemble the clinical course of 
DENV and ZIKV infections and a laboratory confirmation is required for 
diagnosis. The diagnostic criteria of WHO for DENV is either detection of 
the virus by virus isolation or viral RNA or seroconversion of IgM or IgG 





Table 3. Summary of methods in diagnostics of DENV and ZIKV infections from serum. *in 
traveller population longer detection of NS1 Ag has been reported 228, ^cross-reactions 





Viral isolation is no longer in routinely used for diagnostics since the 
method is slow and requires special facilities, demanding manual 
techniques and skilled personnel (Table 3.). In research, by contrast, viral 
isolation is still widely used as it is considered as a golden standard for 
confirmation and typing of the infecting virus.  
The traditional approach to virus isolation of arboviruses has been culturing 
in mouse brain, a method which is still in use 229. Generally, flaviviruses are 
grown in several vertebrate or mosquito cell lines. Vero cells (from green 
monkey kidney epithelium), LLC-MK2 (rhesus monkey kidney) and BHK-
21 (baby hamster kidney) of mammalian origin cells and mosquito C6/36 





Measurement of the IgM and IgG class antibody response against DENV 
and ZIKV infections is widely used in diagnostics. Methods for the antibody 
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detection include enzyme-linked immunosorbent assay (ELISA) and 
immunofluorescence assay (IFA) based methods and 
immunochromatographic rapid tests. Specific IgM antibodies are detectable 
in primary DENV infections in 4-5 days (Figure 8.) and remain in the 
circulation at detectable levels for up to 3 months (Figure 8.); specific IgG 
antibodies are found in about seven days after onset of illness yet may 
remain detectable even for decades (Figure 8.). In secondary infections IgM 
class antibodies are not always measurable at all while IgG antibodies are 
produced within couple of days after onset of illness in levels higher than 
those seen after primary infection 112,227. The kinetics of antibodies against 
ZIKV or markers associating with ZIKV infection is not thoroughly 
understood to date yet comparisons of DENV infection markers and their 
kinetics have revealed some differences.. RNA detection from serum 
suggests that the viremic phase of ZIKV infection is longer, up to two weeks 
after onset of illness compared to week in DENV (Figure 8.) infections. In 
ZIKV infections IgM detection is recommended since day four after onset of 
symptoms, yet there is gathering evidence that IgM is reliably detectable 
approximately 7-8 days after onset of illness 232-235. Lustig et al reported 
ZIKV IgM detection from day two and IgG detection from day five after 
onset of symptoms in traveller population 236. Commercial tests to detect 
antibodies against ZIKV have been developed 237,238; antibody tests for 
detection of IgM against ZIKV are available from several manufacturers 
(Diasorin Incorporated, Inbios International, EuroImmun).  
The differential diagnostics between different flaviviruses, such as DENVs 
and Zika, is complicated by significant cross-reactivity between these 
related viruses and, thus, methods other than antibody detection are often 
required. Also prior vaccinations against other flaviviruses (YFV, JEV, 
TBEV) may result in false positive results in IgG serology. Commercial anti-
DENV IgM tests have proved to give false positive results from patients with 
ZIKV infections 239-242. Tests to detect ZIKV IgM have been shown to have 
high specificity, yet shortcomings in sensitivity of some tests have been 
observed 243. 
The identification of the aetiological agent is difficult and often even 
impossible on the basis of the antibody tests, neutralization assays 
excluded. Neutralization assays are based on the neutralizing antibodies in 
the patient serum interacting with the virus. The interaction inhibits 
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attachment of the virus to cells. These assays provide a specific tool for 
convalescent phase of the infection. Yet neutralization assays require 
facilities and skilled personnel as they include lots of steps, are slow, 
demand a lot of hands on work, cell culture work and BSL facilities. and are 
though not in routine diagnostic use 244,245. The plaque reduction 
neutralizing test (PRNT) has traditionally been considered as a golden 
standard in the differential diagnostics of flaviviruses. In addition to 
neutralization assays detection of the nucleic acids and the virus isolation 
are the most reliable methods for differential diagnostics. 
 
NS1 antigen detection 
 
In dengue infections the NS1 protein is secreted into serum and is therefore 
often detectable during the early days of the disease (Figure 8.). The 
benefits of the NS1 antigen detection include detectability in early phase of 
the disease, the specificity, simplicity of testing and the stability of NS1 
protein compared to RNA. NS1 antigen tests are either ELISA or 
immunochromatographic rapid tests which do not require special facilities 
and are easy to conduct. Moreover, it has been reported that especially in 
primary DENV cases the NS1 ag is detectable notably longer than viral RNA 
246. However, there are some reports of NS1 detection being less sensitive in 
secondary infections 247,248. Pre-existing antibodies in secondary infections 
could interfere with the antigen detection assay by forming antigen-
antibody complexes and they may also influence in more rapid clearance of 
the NS1 antigenemia in secondary infections 248. In addition to ELISA and 
immunochromatographic methods, rapid tests for detection of DENV NS1 
Ag have been developed and methods based on immunosensors and 
detection of optomagnetic nanoclusters and fluorescent nanoparticles 
utilizing immunospot assay are under development 249-251.  
Even though NS1 antigen test has been considered as a DENV specific 
method, some DENV NS1 Ag rapid tests have given false positive results in 
ZIKV infections 252. To date, the proof-of-concept of utilization of ZIKV NS1 
antigen tests in diagnostics remains to be shown and there are not yet 
commercial tests available for the detection of ZIKV NS1 Ag. In dengue 
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infections, NS1 antigen has been shown to be secreted to urine and saliva in 
addition to serum 253-255 which enables non-invasive sampling. In ZIKV 
infections the usability and secretion to different sample materials of NS1 
antigen has to be investigated further. 
 
Detection of viral nucleic acids 
 
There are many assays developed, both conventional RT-PCRs and also 
real-time RT-PCRs to detect dengue and ZIKV RNA and also the variation 
in target regions is wide. RNA detection requires considerably more from 
the infrastructure and personnel of the laboratory when compared with 
serological methods. The detection of DENV RNA is recommended from 
samples taken within the first week of illness, whereas in ZIKV infections 
RNA detection from serum and urine is recommended for the first 14 days 
after onset of symptoms (Figure 8.) 99,239,256-258 It has though been observed 
that the level of viremia is greater in primary than secondary DENV 
infections 248,259,260. Whole blood has also been reported as a sample material 
that contains detectable levels of ZIKV RNA for long periods, up to two 
months, on the contrary to DENV infections, in which serum is considered 
preferable sample material over whole blood 261-263. The viral RNA levels of 
saliva samples of ZIKV patients have been reported to be higher compared 
to serum yet the timing of the presence of RNA in both samples does not 
seem to differ 264. However Paz-Bailey et al found detection of ZIKV RNA in 
saliva rather infrequent when compared to serum 233. Within pregnant 
women with ZIKV infection the duration of viremia has been shown to be 
prolonged. The viral level in the mother’s serum (but not in urine) stays 
stable up to 14 weeks after onset of symptoms; the viral load has been 
reported to be higher in the amniotic fluid than in mother’s serum. 





Figure 8. Timing of different diagnostic methods in primary DENV and ZIKV infections. 
Currently the usability and kinetics of NS1 Ag in ZIKV infections is still unclear. 
 
There is no single assay that would reliably detect infection with DENV or 
ZIKV throughout the clinical course of the disease but a combination of 
tests targeted to the early phase and convalescent phase are needed. In the 
acute phase of the disease, approximately days 1-4 after onset of symptoms, 
methods detecting the virus or its components (RNA or in case of DENV 
NS1 antigen) are the preferred choices. In convalescent phase, 
approximately from day 5 on, methods detecting antibodies (with IgG from 
day 7 on) are recommended to supplement the direct detection of the virus. 
A combination of NS1 antigen testing with detection of IgM class antibody 
tests is widely used in DENV diagnostics 267. This combination enables 
detection of the infection in the early phase but also in later phase, when 
viremia has passed. In ZIKV diagnostics detection of viral nucleic acids is 
combined with antibody (especially IgM) detection. Yet, in dengue endemic 
regions the role of ZIKV IgM testing is hampered by cross-reacting 





5.7 Prevention of DENV and ZIKV infections 
 
There is no specific treatment for DENV or ZIKV infection so the actions are 
taken towards prevention. There are two main strategies; vector control and 
vaccine development. The eradication of the vector mosquitoes has been 
attempted but has not proven a successful strategy in the long term. In 
many countries of South America, for instance Brazil, Colombia and Bolivia, 
Ae. aegypti was eradicated with quite success in the large campaign during 
1947-1970 268. This campaign was extremely efficient and only one DENV-2 
genotype was circulating in the countries with eradication campaign until 
1970s 269. The success of the campaign greatly relied upon the utilization of 
DDT but as it turned out that DDT is carcinogenic, its use was eventually 
banned in 1970s 268,270. As the program waned, Ae. aegypti was rapidly re-
introduced and spread even to regions it had not been present previously. 
To date, it has been highlighted that massive spraying of the insecticides 
does not have notable impact in dengue transmission 271. One way is to 
remove all the possible breeding sites, namely stagnant water around 
houses and elsewhere. Also the utilization of larvicides helps in controlling 
the mosquito breeding. This is an efficient approach which people 
themselves can carry out and it has been stated that the community 
participation in vector control is crucial for its success 271. 
Wolbachia, a bacterial symbiont of insects, has been shown to produce 
resistance against RNA viruses in Drosophila melanogaster 272 and also to 
induce cytoplasmic incompatibility in insects 273, allowing this bacterium to 
spread rapidly amongst the population. These findings arose interest of 
utilization of Wolbachia in MBV control. When a strain of Wolbachia, not 
effecting on the lifespan of the mosquito, was introduced to Ae. aegypti 
population, it was soon observed that mosquitoes became resistant for 
DENV as Wolbachia prevented the dissemination of the virus to salivary 
glands of the mosquitoes and thus reducing the vector competence of these 
mosquitoes 274,275. In addition to Wolbachia, other technologies in biological 
prevention have been developed. Genetic modification to reduce vector-
competence by making the mosquitoes more resistant for DENV infection 
276 and reducing the mosquito population by killing mosquitoes in larval 
stage 277 have been shown to be promising efficient ways in mosquito 
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control. These technologies are still under studies and ways improve the 
methods are explored. In Sterile Insect Technique (SIT), the radiated male 
mosquitoes are released. Their offspring is not viable thus reducing the 
populations 278,279. Considering the increasing resistance of mosquitoes to 
insecticides, Wolbachia SIT technique and genetic modification of vector 
species provide a promising approach to MBV control and decreasing the 
environmental impact of mosquito control as reducing the utilization of 
insecticides and larvicides. Vector control has been calculated to be 
profitable and cost-effective when compared to disease treatment of MBVs 
280. 
Clinical trials are currently ongoing for candidate vaccines against DENV 
and ZIKV. Problem with DENV and probably also ZIKV vaccine 
development is circumventing ADE. With DENV this means that the 
vaccine should raise equal immune response against all the four serotypes 
of DENV. Sanofi Pasteur has 2015 licensed a tetravalent live recombinant 
dengue vaccine, Dengvaxia (CYD-TDV), which is now available several 
endemic countries. The vaccine is registered for use in individuals living in 
endemic settings (age 9-45) and it seems to function well in that population, 
among people with previous exposure to DENV 281,282. However, there has 
been discussion whether vaccine is recommended for person not primed 
with DENV, as the antibodies elicited may predispose the vaccinee to a 
more severe outcome if they get a natural infection 283. There are also five 
other vaccines under clinical trials, in different phases, at the moment of 
writing this thesis. These vaccines are based on live-attenuated or purified 
inactivated viruses and DNA or subunit technologies. In addition there are 
virus-vectored and VLP-based vaccines in preclinical trials 281,284. There is 
not yet licensed vaccine against ZIKV but several vaccine candidates are in 
different phases of trials, some already in clinical trials. As with other 
flaviviruses live-attenuated and inactivated purified vaccines are 
approaches with ZIKV vaccine but also new technologies like mRNA 
vaccines are under development 285,286. 
5.8 Finnish travellers 
 
As for the trips to (sub)tropical regions, the numbers have been constantly 
increasing over the past years. In 2016 Finns made 6,1 million overnight 
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holiday journeys and 1,8 million work-related trips abroad; in 
approximately 350 000 trips the destination was in the (sub)tropics. 
According to Association of Finnish Travel Agents (AFTA) the most popular 
destinations of Finnish travellers during the last years have been 
destinations within Europe. The trips to Middle East and Northern Africa 
have been in increase in recent years. Thailand is the most popular 
destination for long-distance journeys even though within recent years trips 
to Central America and Caribbean area have become increasingly popular. 
AFTAs statistics are based on package tours but they can be interpreted as 
indicative of the travel habitats of Finnish travellers 287,288. 
While DENV and ZIKV are not endemic in Finland, cases are seen regularly 
among travellers returning from visits to endemic areas in the (sub)tropical 
regions. Indeed, along with the increasing numbers of travels to these 
regions 287 and expanding endemic regions, the numbers of cases have been 
estimated to increase every year. Likewise, while no cases of ZIKV were 
recorded in 2006, from 2007 to 2016 79 countries or territories have 
reported ZIKV transmission and 31 countries cases of microcephaly or other 
malformations of central nervous system 289. Of note, the incubation period 
for DENV infections is short (3-10 days) which means that it is not rare that 
the symptoms start already at the destination and the patient is treated at a 
local hospital 181,290 and the case is never recorded in Finland. Furthermore, 
in diagnostics of febrile travellers, DENV infection can be immediately 
excluded from the differential diagnostics if the symptoms start longer than 
two weeks after return, whereas this is not as clear in case of ZIKV infection.  
Travellers have a role in the epidemiology of mosquito-borne viruses as they 
may transport the viruses from endemic to non-endemic areas (and by 
doing so increasing a risk of establishing virus circulation in new areas if a 
suitable vectors are present). Indeed, outbreaks and non-traveller cases 
have been described e.g. following travel-related transmission of CHIKV 
291,292.  
Travellers contracting mosquito-borne diseases may also provide a tool for 
studying epidemiology and molecular epidemiology of MBVs and act as 
sentinels by providing a sign of an outbreak in an early phase. Sometimes 
the (traveller) infections originate in areas with limited facilities for 
diagnostics. As the viremic travellers return to their countries of residence, 
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laboratory confirmation of the virus and possibly even serotyping or 
sequencing can be performed. This offers a view to global circulation of 
MBVs. 
 
6. AIMS OF THE STUDY 
 
1. Study the kinetics and secretion of virological markers of 
dengue infection and their associations with disease outcome 
and other laboratory parameters (Study II) 
2. To explore the utilization of non-invasive samples in 
laboratory diagnostics of dengue virus infection (Study III) 
3. To characterize congenital ZIKV infection to seek evidence for 
causality between ZIKV infection and foetal brain 
abnormalities (Study V) 
4. To study the global epidemiology of DENV and ZIKV using 
Finnish travellers as sentinels (Studies I and IV) 
 
 
7. MATERIALS AND METHODS 
 
7.1 Study samples 
 
The studies are mainly based on serum samples of suspected dengue 
patients sent to HUSLAB, the laboratory service of the Hospital District of 
Helsinki and Uusimaa (HUCH), Department of Virology and biobank with 
archived samples from HUSLAB. The biobank includes serum aliquots, 
stored in -70°C, from all Finnish patients suspected with dengue. Summary 






Table 4 Study samples. Numbers of samples and sample types in studies of the thesis. In 
Study V the tissue samples comprise of placenta, foetal membrane/umbilical cord, rain, 
spleen, lung, liver, muscle and thymus and other samples include plasma (n=1), amniotic 





Serum samples for studies I-IV were samples sent to HUSLAB collected 
from patients suspected to have dengue infection / explored for dengue as 
one of the alternative causes for fever after travel to (sub) tropics. Samples 
for RNA extraction and isolation were stored in -70°C as 100μl aliquots and 
samples for NS1 antigen detection and antibody screening were stored at -
20°C. 
Plasma and PBMC samples in study V, obtained from Sibley Memoriam 
Hospital, United States, were stored in -70°C and -135°C.  
 
Urine and saliva samples  
 
Urine and saliva samples were collected on daily basis during the 
hospitalization from the patients taking part in the study in study III. 
Samples were aliquoted and stored in -70°C. Urine samples were also 
obtained from the patients (studies IV and V) and from the husband of the 
patient urine and semen samples were obtained in study V. All these 
samples were stored in -70°C. 
Study Serum/n Urine/n Saliva/n Tissue Others (n) Total/n Patients
I 5 5 5
II 139 139 93
III 39 50 48 137 14
IV 5 1 6 5
V 6 3 2 8 7 26 2







In study V foetal and maternal tissue samples were obtained from Division 
of Pathology and Center for Genetic Medicine Research of Sibley 
Memoriam hospital after the abortion of the pregnancy. Brain, spleen, 
muscle, lung, liver, placenta, membrane/cord and thymus samples were 
studied. Samples were stored in -70° and homogenized with mortars and 
pestles with sterile sand and suspended in Dulbecco’s BSA supplemented 
with antibiotics prior to use. 
 
7.2 Patient data 
 
Necessary patient data was collected for each study from patients 
themselves, the doctors taking care of the patients’ or from patient records 
within the data of HUSLAB and HUCH. 
The data collected consisted of travel information (destination, duration 
and purpose of the trip), days of onset of illness, symptoms, laboratory 
values, possible co-infections and flavivirus vaccines, duration of 
hospitalization and previous flavivirus infections. 
 
7.3 Research permits 
 
A research permit for collecting the necessary data about the patients whose 
samples were sent to HUSLAB was applied and gained for HUSLAB 
(TYH2014251). This permit included authenticity to obtain data that was 
classified as confidential. This permit covered all the studies of this thesis. 
The permit for data collecting of patients outside HUSLAB area was 
obtained from the Ministry of Social Affairs and Health (STM/2523/2009). 
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The study protocol of work III (HUS DNRO 388/13/03/01/09) was 
approved by the Ethics Committee of the Department of Medicine, HUCH. 
Written informed consent was obtained from all patients. The protocol 
included collection of daily non-invasive samples (urine and saliva) that 
were not necessary for their routine care. 
 
7.4 Immunofluorescence assay (IFA) 
 
Immunofluorescence assay (IFA) was used in all studies for IgG and/ or 
IgM antibody detection. It was also used in studies III and V for detection of 
viral antigens from the cell culture isolates. IFA is in routine diagnostic use 
for DENV and ZIKV IgG in HUSLAB. 
The IFA slides for showing the presence of viral antigen in virus isolation 
cell cultures or antibody determination from patient samples were prepared 
with infected cells. For antibody titer determination Vero E6 cells infected 
with DENV-3 (studies I-V) and ZIKV MR766 (study V) were used as 
antigen. The slides were prepared by infecting VE6 cells with DENV or 
ZIKV and cells were incubated in 37◦C for 7 or 3 days for DENV and ZIKV 
respectively. With virus isolations the slides were prepared when 
subculturing or harvesting. The infected cells were detached and in case of 
slide preparation for antibody determination mixed with clean cells in ratio 
of 3:1. Cells were washed four times with and suspended in PBS. The 
suspension was dropped on the microwell slides and let to dry overnight. 
Cells were fixed with ice-cold acetone for 7 minutes and stored in -70°C, 
prior to use. 
Serum samples were diluted 1/10-1/1280 with PBS and added to IFA slides 
containing the virus infected, acetone fixed cells. The samples were 
incubated on the slides for 30 minutes in 37°C and washed three times with 
PBS. A secondary antibody against human IgG (Jackson ImmunoResearch) 
conjugated with fluorescent label (FITC) was added and after 30 minutes’ 
incubation in 37°C, excess conjugate was washed with three times 5 
minutes PBS and once for 5 minutes in Milli-Q water. For IFA, human 
serum (knowing to contain antibodies against DENV or ZIKV) or 
monoclonal antibodies (against DENV) were used as positive controls. A 
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serum known not to contain antibodies against flaviviruses was used as a 
negative control and PBS to control background staining from the 
conjugate.  
The presence of antibodies in the studied human sera or presence of viral 
antigens in viral culture samples was observed visually with help of 
Olympus BX51 Fluorescence microscope. 
 
7.5 Enzyme-linked immunosorbent assay (ELISA) and 
immunochromatographic rapid test 
 
A commercial test (Dengue Virus IgM Capture DxSelect ELISA, Focus 
Diagnostics, USA) was used to detect antibodies against DENV IgM. The 
test was used according to manufacturer’s instructions. 
NS1 antigen was detected from serum, urine and saliva samples (studies I - 
IV) with Bio-Rad Platelia NS1 Antigen EIA according to manufacturer’s 
instructions. This test is a one-step sandwich format microplate enzyme 
immunoassay. Though the test is only validated for serum, urine and saliva 
samples were treated with the same protocol. 
The lateral flow immunochromatographic Dengue NS1 Ag Strip (Bio-Rad, 
USA) was used in study III for serum and urine samples. Both sample 
materials were processed according to manufacturer’s instructions 
indicated for serum.  
 
7.6 Virus isolation 
 
Virus isolation trials were conducted in studies III and V. All the viral 
isolation trials were conducted in a biosafety level 3 laboratory (BSL-3). 
The tissue homogenates, serum, urine and saliva (study III) samples were 
inoculated to 80% confluent monolayers Vero E6 (green monkey kidney 
epithelium), and C6/36 (Aedes albopictus) cells in 25cm2 culture bottles. 
Prior to infection cells were washed once with Phosphate buffered saline 
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(PBS) and after that 50μl of serum or saliva and 200μl of urine was 
inoculated to cells. After inoculation, cells were incubated for one hour with 
gentle rocking either at room temperature (C6/36) or 37°C (VE6). After 
incubation cells were washed once with PBS and culture medium, L-15 for 
C6/36 and MEM for Vero E6, supplemented with antibiotics (penicillin and 
streptomycin), Fungizone and 2% Foetal calf serum (FCS) was added. 
The cells were checked every other day for cytopathic effect (CPE) and if 
noticed, cells were harvested. If no CPE was observed, cells were 
subcultured to T75 culture flasks after seven days incubation period. After 
24 days, all cells were harvested regardless of CPE. When harvesting an IFA 
slide was made to test the cells for the presence of viral antigens. 
 
7.7 Real-time RT-PCRs 
 
Real-time RT-PCRs were used in all studies to detect the presence of 
flavivirus RNA in serum, plasma, PBMC, urine, saliva, semen and tissue 
samples. The assays were performed with Stratagene MX3005P real-time 
qPCR instrument. 
Dengue real-time RT-PCR used in the studies I-III is an in-house MGB 
probe method developed earlier 258.  
ZIKV RT-qPCR protocol targeting the NS5 gene used in the study V was 
adopted from a previously described method 293 and the MGB probe was 
modified from Faye et al 157,256.  
In studies IV and V nested PCR detecting a wide variety of flaviviruses was 
used. The method is adopted from Moureau et al 294,295. The method targets 
the NS5 gene and is two-step PCR the first round being a SybrGreen real-
time RT-PCR and the second round a conventional PCR.  
A second seminested traditional PCR was conducted for all the samples, 
regardless of the positivity or negativity in the real-time RT-PCR. 2 μl of the 
first round PCR product was used for the nested round amplification. 
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The first and second rounds of the PCRs were pipetted in different 
laboratories to avoid and water controls included to control potential 
contamination risks. 
The results were observed with agarose gel electrophoresis (AGE) using 
1,5% Seakem agarose in 1x TAE buffer. 10μl of PCR product was used in the 
electrophoresis. The results were visualized under UV light from ethidium 
bromide (EtBr) stained gels.  
 
7.8 Other RT-PCR protocols  
 
Reverse transcriptase reaction 
 
RNAs were converted to cDNA for subsequent PCR protocols utilizing 
random hexamers and Expand RT reverse transcriptase enzyme (Roche).  
DENV serotyping nested RT-PCR 
In studies II-III the original serotyping of the DENV strains were performed 
utilizing a protocol and primers of nested serotyping RT-PCR 296 but using 
Expand RT Reverse transcriptase (Roche) for RT reaction and TaqDNA 
polymerase (Thermo Scientific). The first round produces an amplicon of 
511bp of all serotypes but the second-round amplicons length is dependent 
on the serotype of DENV (482bp DENV-1, 119bp DENV-2, 290bp DENV-3 
and 392 DENV-4). The results of all conventional PCRs were confirmed 
with AGE, using 1% Seakem agarose gel stained with either ethidium 
bromide or GelRed (Biotium, United States). For visualization UV light 







E gene PCRs 
 
In studies I-III the E gene PCRs for phylogenetic analyses was utilized. The 
nested method was adopted from Gaunt and Gould 297. 5μl of the cDNA and 
500nM of each primer in total reaction volume of 50μl was utilized in the 
first round PCR and 2μl of the first round PCR product with the equal 
concentration of primers in the second. The PCR protocol for the both 
rounds was 95°C for 10 minutes followed by five cycles of 94°C for 1,5 
minutes, 45°C for 1,5 minutes and 72°C for 1,5 minutes. After that followed 
45 amplification cycles: 94°C for 50 seconds, 55°C for 60 seconds and 72°C 





In all studies of the thesis sequencing of the genes or whole genomes of the 





Samples for Sanger sequencing were prepared for the sequencing either by 
straight purifying the PCR product with ExoSAP-IT™ PCR Product Cleanup 
Reagent (ThermoFisher Scientific). The PCR products were T-A cloned, if 
necessary, to pGEM-T vector (Promega) according to manufacturer’s 
instructions and T7 and SP6 colony PCR. The purified PCR products were 
mixed with sequencing primers, which in all these cases were also the PCR 





Next Generation sequencing (NGS) 
 
In study V next generation sequencing was used to obtain the complete 
coding sequence of the virus strain (FB-GWUH), isolated in SK-N-SH cells. 
RNA was extracted using QIAamp viral RNA Minikit (Qiagen) from the cell 
culture supernatant. In library preparation Illumina TruSeq Stranded Total 
RNA LT with Ribo-Zero Gold sample preparation kit (Illumina) was applied 
and library quantitation step was performed employing NEBNext Library 
Quant Kit for Illumina (New England Biolabs) according to manufacturer’s 
instructions. For sequencing Illumina Miseq system was utilized. The 
sequences were assembled utilizing Bowtie2 using KU509998; 
Haiti/1225/2014 strain as a reference sequence. 
 
7.10 Phylogenetic analyses 
 
Phylogenetic analyses of the viral sequences were conducted in studies I, IV 
and V. 
In study I phylogenetic analyses was based on the E gene sequence aligned 
with sequences from GenBank showing high homology in BLAST (Basic 
Local Alignment Search Tool) and also sequences of representatives of 
different genotypes of DENV-1. Sequences were aligned with MUSCLE and 
the neighbor-joining phylogenetic tree was constructed utilizing the 
maximum composite likelihood method implemented in Mega software. 
In study IV, the obtained 160bp sequence of NS5 gene was aligned with all 
the overlapping ZIKV sequences deposited in GenBank  and in study V the 
complete genome or coding region sequences in GenBank were used and 
aligned with the obtained genome from the foetal brain by ClustalW 
algorithm in Mega software, version 6.06 298. In the construction of the 
phylogenetic tree Bayesian analyses (Beast version 1.8.0) was utilized in 
study IV using Tamura-Nei (TN93+G) model of substitution, strict 
molecular clock and constant population size demographic model. In study 
V GTR+G substitution model, uncorrelated log-normal distributed relaxed 
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molecular clock and Bayesian skyline demographic model were used in 
phylogenetic analyses 299. 
 
7.11 Statistical analyses 
 
In studies II and III statistical analyses was used in the interpretation of the 
results. 
In study II all statistical analyses were performed with R software (R 
Development Core Team 2011). The kinetics of infection markers in serum 
were studied using generalized additive mixed models (GAMM) 300 and 
associations between virological markers (serum DENV RNA and NS1 
antigen) and clinical parameters were studied by regression models in 
patients (n=89/93) from who we could obtain all the data needed.  
In study III SPSS (IBM Corp. Released 2012. IBM SPSS statistics for 
Windows. Version 21.0. Armonk:NY, IBM Corp.) was utilized for the 
statistical analyses of the results. In some cases, the small number of the 
observations limited the analyse methods that were suitable for the analyses 





General patient data 
 
All together this thesis is based on samples of 119 patients with laboratory 
confirmed DENV or ZIKV infection. The age range was 6 – 74 and 53% 
(n=62) were men and 47% (n=55) women (gender of the three children in 
study IV is not known). Most of the patients originated in Finland but 14 
were immigrants from Africa or Asia. The patients in all studies were 
travellers returning from journeys to tropics or subtropics (Figure 9.). The 
continent, most frequently visited by the study patients was Asia (Figure 9.) 
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with four most popular countries of destination: Thailand (n=37), 
Indonesia (n=12), India (n=11) and Sri Lanka (n=9) (Figure 9.).  
Figure 9. The travel destinations of the patients in studies I-V. The countries visited are 
indicated with coloring;. The color gets more intense with more travellers visiting. Some of 
the travellers visited more than one country. 
 
Kinetics and secretion of markers of DENV infection (study II)  
 
In study II, the kinetics of dengue virus infection markers and the potential 
associations of various routine laboratory parameters with disease severity 
were studied from 139 serum samples of 93 patients with a diagnosis of 
acute dengue infection. The diagnosis was based on IgG seroconversion 
between first and last sample and positive IgM result at least from one 
sample. The diagnosis was confirmed by virus isolation, viral RNA detection 
or NS1 Ag detection in 44, 67 and 70 cases, respectively. Based on travel 
history and serological results the infections were considered to be mainly 
primary. In three cases, secondary infection was suspected based on 
antibody responses (moderately high IgG titer in first sample while IgM was 
negative). Although most of the patients were hospitalized with a mean 
duration of hospitalization of 4.5 days, none of them had complications, 
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such as hemorrhages. The travel destinations included Asia, Africa, 
Caribbean, South and Central America. Altogether 72% of the infections 
were obtained from Asia and 50% specifically from Southeast Asia. In 56 
cases (60%), the infecting serotype could be determined either by virus 
isolation or direct RT-PCR and subsequent sequencing. All dengue virus 
serotypes were represented within the study patients: most common were 
DENV-1 and DENV-3 (24/56 and 22/56 respectively). In 17/91 cases (19%) 
co-infections with other non DENV pathogenic microbes were either 
diagnosed or suspected. In most cases these agents were bacteria causing 
gastroenteritis. 
The comparison of the results obtained from dengue NS1 antigen and viral 
RNA detection tests from 139 sera suggested clear differences in the 
detection kinetics of these markers. The NS1 Ag was detectable for notably 
longer period of time than the viral RNA in serum samples. Whereas viral 
RNA was mainly detected on days 2-9 after onset of illness, the NS1 Ag was 
found to be most probably detected from day 2 up to day 15. Individual 
positive samples were still found positive for NS1 Ag up to day 21. 
When all the diagnostic assay (IgM, IgG, NS1 Ag, RNA detection) results 
were considered, it was clear that none of them alone reached a sufficient 
level of sensitivity for the diagnosis of acute dengue virus infection as none 
of them reached 90% of sensitivity when examining all samples in total 
(Table 5.). With the first available serum sample from each patient (ranging 
from day 1 to 25 since onset of fever), or the samples altogether, IgM 
showed the best diagnostic sensitivity (Table 5.). Examining by days of 
acute phase, during days 1-4 after onset of illness, RT-PCR showed greatest 
diagnostic sensitivity, whereas during days 5-8 after onset of illness IgM 








Table 5. Results of individual diagnostic methods in study II for a selected set of confirmed 
dengue patients and their samples. In all categories the method that gave highest positivity 
rate is highlighted. 
 
When combining the assays, the acute phase diagnosis was significantly 
enhanced by using IgM detection in parallel with either NS1 Ag or viral 
RNA detection. The viral RNA or NS1 Ag with IgM detection showed the 
best sensitivity during the first three weeks after onset of illness: 99% and 
97% of the sera, respectively, were found positive with these combinations 
(the proportion of positive samples with combinations of IgG and viral RNA 
or NS1 Ag detection being 98% and 97%, respectively). Combining antibody 
detection (IgG and IgM) gave positive results in 90% of the samples 
whereas with the combination of NS1 Ag and viral RNA detection 75% of 
the samples were found positive. 
The detection rate of NS1 Ag seemed to vary between serotypes during the 
first 12 days of illness but not after that time point; respective differences in 
the detection rates of the different serotypes was not observed in the 
detection of viral RNA. Our results showed that NS1 Ag was detectable from 
all the patients with DENV-1 infection while from patients with DENV-3 






Associations of markers of DENV infection with disease outcome 
and other laboratory parameters (study II) 
 
We found no correlations between the detected viremia and the outcomes of 
the disease when individual symptoms were considered. However, the 
presence of viremia was found to correlate with the probability of 
hospitalization and the level of viremia, as determined from the relative 
RNA levels derived from the real-time RT-PCR Ct (cycle treshold) values. In 
contrast, neither the positivity of the NS1 antigen test nor the level of the 
antigenemia correlated with either hospitalization or length of 
hospitalization. NS1 antigenemia, derived from the optical density value, 
was found to be associated with fatigue and gastrointestinal symptoms 
(abdominal pain and diarrhea). 
Leukopenia, thrombocytopenia and elevated liver transaminase (ALT, AST) 
levels are characteristic for dengue fever and elevated hematocrit and 
hemoglobin levels may indicate plasma leakage in dengue patients. The 
performed analysis suggested associations between clinical laboratory 
parameters and a positive test result in either NS1 ag or viral RNA The 
overall NS1 antigen positivity at the time of hospitalization was associated 
with increased probability of leukopenia and thrombocytopenia and 
elevated ALT level whereas the level of antigenemia was found to correlate 
positively with maximum hemoglobin level and levels of hematocrit and 
liver transaminases (ALT, AST).  
 
Secretion and kinetics of viral RNA and NS1 Ag to urine and 
saliva (studies III and IV) 
 
The study population consisted of 14 travellers (Study III) each of whom 
was interpreted to have a primary dengue infection with no severe 
complications. The inclusion criteria were suspected dengue infection and 
positive dengue NS1 Ag rapid test result from serum sample. All the 
patients, with one exception, were hospitalized and samples of urine, saliva 
and from some patients also serum, were collected daily during the 
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hospitalization. The most common symptoms included fever, rash and 
headache. The origins of the infections were in Southeast or South Asia and 
Africa. All DENV serotypes were represented (DENV1-4). 
The methodologies developed by the manufacturers for serum samples were 
applied as such in this study on urine and saliva samples and were found to 
be applicable in general for the detection of DENV NS1Ag and RNA from 
urine and saliva, although some problems were encountered with saliva as 
discussed below. (Figure 10.). Virus isolation was not successful from any 
urine or saliva samples tested, regardless of the success in virus isolation 
from a corresponding serum sample. A cell culture isolate was obtained 
from 4/8 of the tested sera and subsequent sequencing showed these to 
represent serotypes DENV-2 (n=3) and DENV-4 (n=1). 
 
NS1 Ag detection rates and kinetics 
 
The NS1 Ag was detected from all available sample materials collected 
between days 1-13 after the onset of symptoms. The results obtained from 
the different sample materials however showed substantial variation in NS1 
Ag detection rates within this timespan. NS1 Ag detection from serum 
showed the greatest detection rate overall as all but one of the serum 
samples were tested positive (Figure 10). Overall detection rate from serum 
was 97.3% while it was 54.2% and 55.5% for urine and saliva, respectively. 
Several urine and saliva samples showed borderline results, which were 
considered as negative (Figure 10).  
 
RNA detection positivity rates and kinetics.  
 
The kinetics of the RNA detection from saliva did not differ notably when 
compared to that observed from serum. Of these two sample materials, 
serum seemed superior with a 100% sensitivity of detection during days 1-6 
as compared to 71.4% from saliva; the overall sensitivity (days 1-13) was 
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70% and 60% for serum and saliva, respectively. However, the kinetics of 
RNA detection from urine was found to differ from that recorded from 
saliva and serum samples as viral RNA was detectable in a later phase from 
urine than from serum and saliva. The overall detection rate of RNA from 
urine was shown to be 64%. However, the detection rate of RNA detection 
from urine was superior to other sample materials during the days 7-13: 
74% of the samples were positive for viral RNA from urine but only 31% and 
50% from serum and saliva, respectively. The RNA detection from a urine 
sample proved positive for each of the study patients 14/14 from at least one 
of the tested time points; whereas only 10/14 patients were found positive 
for viral RNA in any of the tested saliva samples (Figure 10).  
 
Figure 10. Results of viral RNA and NS1 Ag detection in 14 patients. Samples were taken of 
serum, urine and saliva on the given days following the onset of symptoms. Greyzone 
indicates a repeated borderline result. 
 
Statistical analyses showed that urine NS1 Ag levels correlated positively 
with both urine total protein levels and NS1 Ag levels in saliva. Neither RNA 
nor NS1 Ag levels of urine correlated with urine osmolality. NS1 Ag levels of 
serum and saliva correlated with each other but not with urine NS1 Ag 
levels. Of the basic laboratory parameters, urine NS1 Ag levels were found 
to correlate with decreased platelet levels. 
In study IV flavivirus RNA was detected from a patient urine sample 
whereas the sera remained negative. (Figure 11.) (serum taken 7 days and 
urine 8 days after onset of illness). Subsequent sequencing and 
phylogenetic analyses revealed that the infecting virus was ZIKV belonging 
to epidemic Asian lineage. Patient’s serum sample was positive for DENV 
IgG (IFA) and low positive for IgM (Figure 11.) while no DENV NS1 antigen 




Figure 11. Timeline and laboratory results of the traveller case of ZIKV infection from 
Maldives in 2015. Serum sample was tested for DENV IgG, IgM and NS1 Ag. 
 
ZIKV congenital infection (study V) 
 
In study V, the patient was a pregnant woman who had been travelling with 
her husband in Central America, and been heavily bitten by mosquitoes, in 
November 2015. When she returned from the holiday, she got symptoms 
(fever, rash) consistent with ZIKV infection. First suspicions of the 
association of ZIKV infection of the mother and microcephaly of the foetus 
had just been published in the lay press during this time. Ultrasonographic 
examinations showed no abnormalities at gestation weeks 13, 16 and 17. 
Yet, a blood sample was taken from the mother four weeks after onset of 
symptoms and this was found positive in pan-flavi RT-PCR and subsequent 




Figure 12. The timeline and the laboratory results of the ZIKV congenital infection. From 
New England Journal of Medicine, Driggers R et al, Zika Virus Infection with Prolonged 
Maternal Viremia and Fetal Brain Abnormalities, 2016 Jun 2;374(22):2142-51. Copyright 
© (2017) Massachusetts Medical Society.  Reprinted with permission. 
 
ZIKV RNA from mother’s serum sample was detected prior to any notable 
abnormalities on ultrasonography examination. The patient obtained the 
infection during gestation week 11. ZIKV RNA was detected in serum 
sample taken at gestation week 16 (and 21), whereas ultrasonography 
examination of the foetus at gestation weeks 13, 16 and 17 did show no 
evidence of calcifications or microcephaly (Figure 12.). Ultrasonography at 
gestation week 17 showed abnormalities in the foetal brains and head 
circumference measurements decreased between gestation weeks 16-20 
from the 47th percentile to the 24th percentile. Explicit brain abnormalities 
were detected at gestation weeks 19 on ultrasonography and 20 on magnetic 
resonance imaging (MRI). The pregnancy was terminated on gestation 
week 21. 
ZIKV RNA was detected from mother’s serum up to 10 weeks post infection, 
until the abortion was carried out. Serum samples taken after the abortion 
were negative for ZIKV RNA. Samples taken on the day of the abortion from 
membrane/cord, placenta, amniotic fluid and spleen, liver, lungs and 
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muscle of the foetus were positive for ZIKV RNA whereas thymus was 
negative. The samples from the spouse of the mother (and the father of the 
foetus) - serum, urine and semen - were all negative for ZIKV RNA but the 
serum sample showed IgG and IgM class antibodies against ZIKV virus with 
titers of 1:320 and 1:20 five weeks after the infection. From mother’s urine, 
peripheral blood mononuclear cells (PBMC) and saliva ZIKV RNA could not 
be detected. Serum samples from the mother showed IgM and IgG class 
antibodies against ZIKV with titers of 1:80 and 1:640 five weeks after the 
infection (Figure 12.). 
Isolation of ZIKV was successful from the brain tissue of the foetus in SK-N-
SH and VeroE6 cells but not in C6/36 mosquito cells. From the other 
studied tissues (membrane/cord, placenta and spleen) or mother’s serum 
the isolation was not successful. The replication of the virus was observed as 
decreasing CT values in a ZIKV real-time RT-PCR test of the culture 
supernatants sampled and studied daily. The replication of the virus was 
observed since day one after inoculation in SK-N-SH cells and after three 
days in VeroE6 cells. The presence of viral antigens in the cells was shown 
using IFA and the presence of the virus was confirmed by observing virions 
compatible with description of a flavivirus in electron microscopy (EM). 
Additionally, a complete coding sequence was obtained from the culture 
supernatant by NGS.  
 
Molecular epidemiological studies from travellers (studies I, IV and 
V) 
 
In study I we reported five Finnish travellers returning from Madeira in the 
end of 2012 diagnosed with DENV infection. All five seroconverted for IgG 
against DENV and showed class IgM antibodies against DENV. Three out of 
five were also positive for DENV NS1 antigen. From two patients DENV 
RNA was detected and found to represent DENV-1. Phylogenetic analysis 
showed the Madeiran origin strain to associate with American/African 
genotype strains known to circulate in South America. 
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In study IV a Finnish traveller was diagnosed with flavivirus infection 
turning out to be  ZIKV infection originating from the Maldives. At the time, 
no previous reports of the existence of ZIKV within the area of Western 
Indian Ocean had been published. The sequence analysis suggested the 
Maldives strain to represent the epidemic Asian lineage which had caused 
the outbreaks of Yap Island, French Polynesia and later in the Americas and 
the Caribbean region.  
The complete genome sequence of ZIKV strain isolated from the foetal 
brain tissue in study V (supernatant of the SK-N-SH cell culture, day 5 was 
sequenced using NGS methods. This virus was shown to be of Asian lineage 
in phylogenetic analyses and to share highest homologies with Guatemalan 
strains originating from cases with mild disease. This virus, designated as 
FB-GWUH-2016, was identified to have eight amino acid substitutions 
compared to other American ZIKV sequences available in the GenBank 
database. Five amino acid substitutions were found to be unique to FB-
GWUH-2016 strain and three where shared with the Guatemalan strains 





With the emergence of dengue, and more recently Zika virus, coupled with 
the expansion in the distribution of many MBVs, the urgent need for 
specific diagnostics and surveillance of the circulation of these viruses has 
been highlighted. Traditionally, a venous blood sample has been used to 
diagnose cases of both dengue and Zika. This has limitations, however, 
since collecting blood samples from small children can be difficult, and 
collecting and storing venous blood from patients in remote areas, may be 
impractical. To date it has been observed that other sample materials are 
suitable and in some cases even superior to serum in DENV and ZIKV 
diagnostics 255,301-303. The kinetics of the markers of DENV infections have 
been mainly studied in endemic settings, representing also secondary 
infections and severe disease cases. Travellers usually experience mild 
primary infections and thus their samples provide another insight into the 
variation of viral markers and their kinetics in a different study population. 
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The observation in 2015 in Brazil of the increased number of microcephaly 
cases interrelated to the epidemics of ZIKV was alarming and caused World 
Health Organization (WHO) to declare the Public Health Emergency of 
International Concern 304 The causality of congenital ZIKV infection and 
malformations in the development of the central nervous system of the 
foetus was soon under heated investigation. Travellers, as sentinels, often 
provide an opportunity to discover viruses from new areas or to observe an 
outbreak in its early phase. 
In this thesis,  samples obtained from returning travellers, including a 
unique collection of all Finnish suspected dengue cases from the last 18 
years, were used to explore the kinetics of the markers of DENV infection.In 
addition, the potential of different sample materials for use in the 
diagnostics of DENV and ZIKV infections were exploredfrom a mainly 
flavivirus naïve population. These samples also facilitated the study of 
molecular epidemiology of the DENV strain responsible for the Madeiran 
outbreak, and revealed the circulation of ZIKV in the Maldives. Finally, 
congenital ZIKV infection with a mother’s prolonged viremia was 
characterized and infection of the foetal brain was confirmed by the 
isolation of ZIKV from the affected tissue. This provided evidence for the 
causality between mother’s ZIKV infection and brain abnormalities of the 
foetus. 
 
Insights into diagnostics of DENV and ZIKV 
 
Kinetics of markers of DENV infection 
 
Studying the kinetics of the infection offers tools for assessing efficient 
diagnostics for each phase of the disease. More comprehensive data 
including patients with complicated DENV infections, for example with 
haemorrhages, are required in order to confirm the factors underlying the 
severe disease outcome and identifying the risk factors. 
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The kinetics of viral markers in primary and secondary dengue infections 
differs, as many previous studies have shown. The detection span of NS1 
antigen seems to be notably longer in primary 228,305 than in secondary cases 
248,306. In secondary cases IgG antibodies are detected in a very early phase 
of the disease 179 and IgM may even remain negative. In primary cases IgM 
class antibodies will be detected first, starting from days 4-5 while IgG 
antibodies become measurable only after day 7 179 This implies that more 
studies covering the kinetics, in populations both living in the endemic and 
non-endemic areas (e.g. travellers), are needed to cover the entirety of the 
kinetics of markers of DENV infections. Travellers differ from the 
populations living in endemic areas not only by having usually primary 
infections versus the typically secondary infections of populations from 
endemic areas but also by the genetic background. Different 
recommendations for methods of choice in diagnostics may also be needed 
for populations living in endemic and non-endemic regions. 
It has previously been observed that the DENV NS1 Ag test detects the four 
DENV serotypes with unequal sensitivity, favouring the detection of NS1 Ag 
from DENV-1 infections 238,307. Whether this is due to unequal recognition of 
the antigens by the anti-NS1 antibodies used in the antigen detection assays 
or differences in production rates of NS1 antigens in infections of different 
DENV-serotypes, genotypes or lineages is unclear. It has also been observed 
that NS1 antigen tests perform better in primary infections than in 
secondary 238,246,307. The prevailing theory is, that in secondary infections, 
the existing antibodies against NS1 protein form immunocomplexes with 
the antigen and thus inhibit the recognition of the antigen by the anti-NS1-
antibodies of the antigen capture tests 247. Even though our patient material 
included only three cases suspected as secondary cases, all of these actually 
were negative in NS1 Ag test while positive for viral RNA.  
Besides the detection rate of NS1 Ag, the DENV serotype has been reported 
to affect the level and duration of viremia. Both in primary and secondary 
cases it has been observed that viremia is higher in DENV-1 infections  and 
the duration is longer when compared to infections of other DENV 
serotypes 248. This has an impact, not only on diagnostics but also on the 
transmission of the virus.  
67 
 
Association of viral markers to disease outcome and other laboratory 
parameters in DENV infection 
Identifying the factors affecting the outcome of the illness provides insights 
into the pathogenesis of the infection, but may also help in determining the 
patients at risk for complications. The complicated disease forms require 
hospital care, thus identifying the patients at risk could have practical 
implications for patient monitoring needs. The knowledge of the factors 
affecting the disease outcome is still incomplete and this fact hampers also 
the development of the methods of treatment. Our patients with DENV 
infections mainly presented with primary infections with no complications. 
The duration of hospitalization varied and longer hospitalization was 
considered as sign of more severe disease. Our patient sample showed that 
NS1 antigenemia and high-level viremia correlated with disease outcome in 
terms of length of hospitalization. The observations suggest that there is a 
gradient of disease severities within the “non-complicated, mild dengue 
fever” of travellers. Also the markers predicting a more severe disease in the 
mild disease forms seem actually to be the same markers that have been 
identified in the endemic populations to predict more severe disease 
outcomes of also more complicated dengue, including dengue haemorrhagic 
fever 308,309. The hallmarks of DF such as leukopenia, thrombocytopenia and 
elevated liver transaminases were also observed in traveller patients. The 
elevated hematocrit, known to reflect the plasma leakage in severe forms of 
dengue 310 was also observed in some of the studied patients with 




Current diagnostic recommendations by the US CDC include the testing of 
ZIKV RNA from serum or urine during the first 14 days after the onset of 
illness 311. The viremic phase in ZIKV infections, or at least the length of 
detectability of viral RNA after onset of symptoms, seems to be longer as 
compared to those observed in DENV infections. Notably, the detection of 
viral RNA from blood samples of patients with ZIKV infection seems to 
follow the path of WNV. In WNV infections the period where RNA is 
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detectable from serum seems to be slightly longer than in DENV infections 
but notably longer from whole blood samples. 233,245,312,313.  
The transmission of ZIKV from mother to foetus has been a totally new and 
alarming feature of flavivirus infections. The infection has, in most cases, 
been asymptomatic for the mother and yet the virus has been transmitted to 
the foetus and caused severe developmental disorders, emphasizing the 
need to carefully monitor pregnant women at risk of ZIKV infection. We 
demonstrated prolonged viremia, possibly due to the release of the virus 
from persistent infection in the foetoplacental system, into the mother’s 
circulation. This assumption was later supported by results of Suy et al and 
Meaney-Delman et al who also reported prolonged viremia in pregnant 
women 265,266. This feature was unexpected but has now been supported by 
several studies, and ultimately has changed the diagnostic 
recommendations of ZIKV RNA sampling and testing of pregnant women. 
The persisting viremia enables the screening of mothers whose babies have 
an increased risk of ZIKV derived developmental disorders. This 
observation has already impacted the CDC, who has recommended nucleic 
acid testing for pregnant women up to week 12 after exposure 311. The rapid 
change in emergence of Zika virus and the alarming transmission routes, 
from mother to foetus and via sexual transmission, and associated 
complications shows the capability of the viruses to obtain new features that 
can have an impact in their virulence, epidemiology or transmission. As 
mosquito-borne viruses are relatively rapidly evolving RNA viruses, these 
mutations can take place over a short period of time.  
The associations of the mother’s prolonged viremia to zika congenital 
infection and its outcomes are important aspects of ongoing and future 
studies. The diversity of the outcomes of ZIKV congenital infections in the 
developing foetus and also the effects that may become visible after birth 
and later during the childhood are currently not well known. The most 
severe forms of congenital infections including microcephaly, once 
detected, are reasons for considering termination of pregnancy. Detection 
of congenital ZIKV infection by measuring the mother’s viremia may 
facilitate earlier diagnosis of the congenital infection compared to 
ultrasonography which is currently relied upon. It is still unclear, however, 
when during maternal infection, or which aspect of infection leads to these 
69 
 
congenital defects in the foetus, making the interpretation of maternal test 
results problematic without further research. 
 
Differentiating DENV and ZIKV 
 
It is well known that antibodies against different flaviviruses cross-react 
and that causes challenges in diagnostics, especially in the later phases of 
the disease when viremia and NS1 antigenemia have passed and these virus 
specific tests are not choices for the diagnostics. DENV IgM ELISA has been 
reported to give positive results in ZIKV infection by us and also by others 
240,314. The commercial ZIKV combined IgM/IgG test (Euroimmun) has been 
reported to be quite specific but with lower sensitivity when compared to 
IgM-capture ELISA assays (InBios and CDC) 315,316. There may be variation 
in the specificity of the tests of different manufacturers. The DENV NS1 Ag 
ELISA test (Bio-Rad) has not been reported to give false positive; cross-
reaction neither suspected results in our studies nor reported by others yet 
a positive DENV NS1 ag test may not rule out ZIKV infection, as double 
infections are also possible. However, we observed that Bioline DENV NS1 
Ag rapid test (Standard Diagnostics Ink., Republic of Korea) gave positive 
results when tested with culture supernatants from different Zika virus 
isolations 317. Although the tested sample did not represent a clinical 
sample, it demonstrated that antibodies utilized in the detection of DENV 
NS1 also recognized ZIKV NS1. In studies IV and V cross-reaction derived 
false positive results were observed in DENV serology when patient samples 
of ZIKV infections were tested. Currently, as the diagnostics of DENV in 
many countries is based on clinical findings and possibly serology, the risk 




The use of non-invasive sample materials and capillary blood samples have 
been studied widely in endemic populations but to lesser extent in traveller 
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populations 253,255,301,306,318-323. In dengue infections NS1 Ag, viral RNA and 
also antibodies against DENV are shown to be detectable from saliva and 
urine 253,301,320,322,323. 
The use of urine as a diagnostic material in DENV & ZIKV infections 
(studies III and IV)  
Although it may be suspected that DENV and ZIKV, related viruses would 
have similar profiles regarding diagnostic procedures, these have been 
observed to differ. In both infections the kinetics of the secretion of RNA to 
urine seems to differ from that of serum. In DENV infections the peak of the 
levels in urine takes place notably later (from day 6 on after the onset of 
symptoms) than in ZIKV infections, and moreover, the viral loads, in terms 
of viral RNA, seem to be higher in urine than in serum in light of recent 
studies 255,301. In ZIKV infections, the evidence is more controversial than in 
DENV infections, where naturally more research data is available. Some 
studies show longer period and higher levels of the ZIKV RNA in urine than 
in serum 240,303 but another exhaustive study reports longer duration of 
ZIKV RNA detection from serum than urine, two and one weeks after onset 
of symptoms respectively 233. In case of Zika, further investigations of the 
kinetics of infection and the secretion of markers of viral infection to 
different sample materials are needed. Even though it has been shown that 
the serotype of DENV has impact on the level and duration of viremia and 
so to the detection span of the viral RNA from serum 248 it remains to be 
explored whether this is also valid for detection of DENV RNA from urine. 
The observation that the time frame and peaks of viremia (or RNAemia) 
from sera and urine differs, is interesting also from the viewpoint of the 
course of the infection in the human body, which is currently not well 
known. The unsuccessfulness of the urine sample DENV isolation in 
comparison to the success from the serum was also a surprise and 
interestingly, there are no other reports either of isolation of DENV from 
these sample materials. This may be related to the chemical properties of 
urine. However, isolation of other mosquito- and tick-borne flaviviruses, 
including ZIKV, from urine has been reported 324-326. 
Urine as a sample material represents features that should be standardized 
in order to get comparable results, for instance incubation time in bladder. 
It would be easily an assumption that the dilution, and thus the amount of 
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fluids a patient has drunk and the incubation period of the urine in the 
bladder, would have impact on the results. Yet, the lacking correlation 
between urine osmolality and both urine RNA and NS1 Ag levels 255 suggest, 
that this might not play a major role in using urine as a test material. 
 
Saliva as a diagnostic material in DENV diagnostics 
 
Saliva as a diagnostic material offers interesting possibilities for diagnostics 
e.g. in terms of rapid tests. However, it seems (for at least now) that saliva 
as a diagnostic sample material is complex as compared to serum and urine. 
The detection of viral RNA in saliva seems to be infrequent when comparing 
to serum and urine in both DENV and ZIKV infections 233,255. The detection 
rates may be influenced by the saliva as a sample material, e.g. the used 
RNA extraction methods may not be optimal for saliva due to composition 
and enzymatic activities of components saliva. Additionally, saliva may 
contain inhibitors that may hamper RNA detection. Also the detection of 
NS1 from saliva resulted not in as consequential conclusions as from urine. 
This may be due to differences in sampling or sample quality, if the person 
has ate just before sampling, the inhibitors in saliva, the composition of the 
sample etc that may affect NS1 ag detection from saliva. Most of these could 
theoretically be avoided with a specifically developed rapid test that would 
just be stick-to-mouth principle (this also would standardize the sampling). 
To increase the usability of saliva in diagnostics, developing specific buffers 
and reagents may be required. If the methodological challenges in saliva 
diagnostics could be overcome, saliva as a sample material may provide 
wide usability. 
 
Emergence and complications of ZIKV 
 
As the ZIKV epidemics hit Brazil a question emerged of associations 
between ZIKV infection of pregnant women and children born with 
microcephaly due to a major increase in microcephaly cases in the region 
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327. We were able to show in the studied patient case the causality between 
foetal infection with ZIKV and abnormalities in brain development. We also 
showed the prolonged viremic phase of the mother due to the congenital 
infection. Prolonged viremia of pregnant women is currently noted as a 
common phenomenon 265,266,311. In addition neurological complications, 
including GBS and meningoencephalitis, of adults were observed since 
French Polynesian outbreak 214,216,289. As ZIKV was previously considered as 
a moderately harmless virus with mild symptoms and low occurrence, the 
current epidemic with new and striking disease associations caused WHO 
to declare the Public Health Emergency of International Concern (PHEIC) 
on February 1, 2016. 
Besides the alarming complications, transmission routes not typical for 
flaviviruses, namely sexual and prenatal transmission, were associated with 
ZIKV infections 149,151,157,328-330. The complications associated with ZIKV 
infection may, however, have become observable simply because of the high 
case numbers in the current outbreak. Prior to outbreak of Yap island, less 
than 20 human cases had been reported for five decades.  
 
Global epidemiology of DENV and ZIKV 
 
With help of case studies of the travellers the molecular epidemiology and 
circulation of both ZIKV and DENV were studied. This resulted in 
observations of new areas for ZIKV circulation and provision of data for 
molecular epidemiology of Madeiran dengue epidemic in 2012.  
The case of a Finnish traveller revealed the presence of ZIKV in Maldives;  
our observation was the first one reported from the country. The nearest 
reports of the ZIKV infections previously were from mainland of Southeast 
Asia. After our notification for authorities in the Maldives, the authorities of 
Maldives have taken action to survey the situation. CDC has now 
announced the finding of mosquitoes infected by ZIKV reported by public 
health officers of the Maldives 331. Yet, no further reports of the human cases 
from Maldives are found in PubMed in the time of writing this thesis. As 
most of the ZIKV infections are asymptomatic or the clinical picture is really 
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mild and resembles dengue and CHIKV infections, known to circulate in 
Maldives this patient case would have easily been misdiagnosed on the 
basis of symptoms alone. With serology testing the case showed 
characteristics of an acute dengue infection. Without PCR testing, which 
was initially performed to find out the infecting serotype of DENV, this case 
would not have been identified as ZIKV. 
The outbreak in Madeira was the largest autochthonous one Europe has 
had to face so far. The vector in this outbreak was Ae. aegypti which 
presence has been reported from Madeira (Funchal) 2005 332. The virus 
causing the outbreak was shown to be DENV-1, American/African genotype 
with greatest probabilities of originating from Venezuela 43,333. Considering 
the expanding distribution areas of Ae. albopictus, this outbreak most 
probably will not be the last one. Viremic travellers returning to their 
homelands with infestation of suitable vector species may create a risk for 
outbreak as it has been suggested to happen in Madeira based on peak of 
dengue importation by travellers and the timing of the outbreak 43. 
One interesting viewpoint in European dengue outbreaks is that majority of 
them have so far been shown to be caused by a single serotype, namely 
DENV-1. Knowing that all four serotypes are circulating throughout tropics 
and subtropics, a question arises of why DENV-1 seems to be dominating 
type in European cases. Is it due to its prevalence in the areas European 
travellers like to travel or could it be that DENV-1 produces highest level of 
viremia or more severe symptoms-leading to seeking medical care during 
primary infections and would in that way be most probable cause of 
outbreaks when imported to previously unaffected regions by viremic 
travellers? Also the question of competence of European vectors for DENV 
can be raised. As the mosquito species in different geographical areas differ 
from each other, the vector competence for different DENVs might vary. 
However, within the Finnish travellers, viremic patients of all serotypes 
have been detected. As cell culture virus isolation is considered less 
sensitive than mosquito inoculation, we would expect these patients to be 
infectious for suitable mosquito vector species. Taking into account that in 
last few years DENV-2 has displaced DENV-1 as the most common serotype 
circulating in South East Asia, Europe might experience more outbreaks 
caused by DENV-2 in future. On the other hand it has been observed that 
longer viremia and higher viral loads are often associated with DENV-1 
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infections compared to infections caused by either DENV-2 or DENV-3 248. 
This could at least partly explain the DENV-1 outbreaks in Europe as the 
travellers returning from endemic areas with DENV-1 infection stay viremic 
longer, thus increasing the possibility of transmission by the local vectors. 
Cases from the Madeiran outbreak were diagnosed across Europe and also 
in Finland 44,334. Madeira lies near to North African coast and its subtropical 
climate has enabled the establishment of Aedes aegypti which was first 
recorded there in 2005 335. The onset of the outbreak was in the beginning 
of October 2012 and it continued to February 2013. More than 2000 cases 
were reported, out of these 78 imported to 13 countries in Europe, 7 cases to 
Finland 44,334. The origin of this outbreak has been proposed to be in South 
America and specifically Venezuela on the basis of importation index and 
also viral phylogeny 43,333,334. 
Ae. albopictus is known as highly invasive species and it is adapted for 
breeding in various environments. The first occurrence of this species in 
Europe was reported in 1979 from Albania 336 and to date it has been 
established in Southern Europe and Central Europe. In Eastern and 
Northern, Europe the winter temperature is likely to be the limiting factor 
for distribution of Ae. albopictus, as the winter temperatures are too low for 
the survival of either adults or eggs. In Southern Europe, the temperatures 
of the summers set the limits as the optimal development of Ae. albopictus 
requires temperatures between 25-30°C 336. Yet it is not known in detail why 
this or other mosquito species survive in some environments and not in 
others- thus which are the critical factors behind establishment. It could be 
speculated if the micro environments, like greenhouses, would enable the 
spread of small communities more easily also to otherwise “unsuitable” 
regions.  Surveillances of the greenhouses might be needed as it is known 
that in Netherlands populations in these environments have been observed. 
When flowers are traded from country to another, also mosquitoes might 
bet transported. Establishment of this mosquito species offers 
infrastructure for MBVs, such like Zika and dengue, which do not need 
other vertebrate hosts for amplification. Also Ae. aegypti has been 
established in Europe previously but has disappeared from the mainland 
(except the easternmost Europe; Georgia and Russia) whereas it is 
established in Madeira 85,332,337,338. Re-establishment of this efficient vector of 
for example ZIKV, DENV and CHIKV to Continental Europe would 
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probably have an effect on the MBV virome and transmission dynamics in 
Europe. 
Considering situation in Finland, there already exist possible vectors (for 
example Culex pipiens) for WNV and USUV. Knowing the implications of 
warming climate on many species of insects it is probable that also the 
occurrence and prevalence of mosquito species in Finland will 
change/expand in the future decades. This will enable entrance for also new 
mosquito-borne viruses. The active traffic of migratory birds has already 
probably enabled spreading of Sindbis virus to Finland in 1970s 339. The 
expanding distribution areas of the vector mosquitoes does not affect only if 
introduced to Finland. The existence of vector species and MBVs in Europe 
increases greatly the volume of Finnish travellers exposed to these viruses 
and so highlights the need of accurate diagnostics and consciousness of 
possibilities of MBV infections also with travellers returning from Europe. 
The expanding distribution areas of the vector mosquitoes and along that, 
the viruses will produce challenges in the future. Screening of the travellers 
offers tools not just in managing the care of that patient but also in 
monitoring the outbreaks and the global movement of the viruses. While 
the mosquito species establish in new areas it is highly important to 
monitor the viruses that are imported to these areas in terms of disease 
distribution control. The DENV outbreak of Madeira, the ZIKV case from 
Maldives (studies I and IV) show the role of travellers in both as a risk to 
distribute the virus into new, formerly naïve areas but also to uncover the 
circulation of the virus in areas that are not known to be endemic. As 
viremic travellers, returning from dengue endemic areas have been 
considered as a main route for the virus transmission to non-endemic areas, 
rapid diagnosis does not serve solely as managing the individual infection 
but also assists in controlling the spreading of the virus for example by 
guidance of the patients to avoid contact with the local mosquitoes. It has 
been reported that the only limitation for establishment of DENVs is the 
existence of suitable vectors86 which emphasizes the necessity of recognition 
of viremic patients especially in areas infested with Aedes albopictus or 
aegypti to prevent subsequent transmission by local mosquitoes. 
There is no special medication against Zika or dengue or vaccine against 
Zika. The dengue vaccine on market in the Americas has its disadvantages 
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which restrict its use for naïve populations like travellers. The importance 
of vector control as preventive action against these viruses, as well as 
against many other mosquito-borne pathogens, is major. Moreover, this 
emphasizes the necessity of monitoring the outbreaks and global circulation 
of these viruses and their vectors. Exact diagnostics is not just to manage 
the patient but also to benefit population and observing possible outbreaks 
as soon as possible in order to control them. 
 
10 CONCLUDING REMARKS 
 
 
The distribution, occurrence and prevalence of vector-borne diseases are 
under changes due to environmental changes causing the changes in 
distribution areas of the vectors and also the increase in mobility of humans 
and the global trade. This tendency can be seen both in tick-borne and 
mosquito-borne infections. Also new vector-borne diseases are emerging. 
This causes challenges in differential diagnostics and emphasizes the need 
for optimized laboratory diagnostic protocols including methodologies and 
sample materials used. Understanding the kinetics of the markers of the 
infection and secretion of them to different sample materials helps to find 
the effective combinations for diagnostics at different stages of the disease. 
Optimized early diagnosis helps also in patient management. 
The changing and expanding distribution areas of vector-borne flaviviruses 
will probably also effect to the epidemiology of these diseases in the future. 
As increasing number of people live in areas with available predisposition to 
some of these viruses, it will mean that large populations have old flaviviral 
immunity. This will have implications to interpretation of serological test 
results, but may also have other effects. It remains to be seen how the pre-
existing, potentially cross-reactive and non-protective immunity will affect 
to disease outcome and virus transmission. Old immunity against DENV is 
thought to cause more severe course of infection with Zika virus via 
mechanisms of antibody-dependent enhancement. Whether this is the case, 
will remain to be properly investigated. In Europe, Usutu and West Nile are 
endemic in large areas. Within decades, there probably will be high 
seroprevalence against these viruses in the endemic regions. Whether the 
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population immunity against these viruses would protect against or 
enhance potentially emerging heterologous flavivirus infections, such as 
DENV or ZIKV in Europe will remain to be seen.  
Infected travellers provide a possibility to identify a causative viral agent 
from local circulation perhaps already before the outbreaks and spread 
distribution areas of the MBVs. In the endemic areas the resources do not 
often allow thorough surveillance of MBVs and the limited resources may 
be targeted to outbreak situations. This however does not allow the 
understanding of the complete picture, as the increase of symptomatic 
patient cases is often only the tip of the iceberg that has become visible. The 
information about the global circulation of the MBVs gained from traveller 
cases promotes the predictions about future distribution areas and disease 
burden of these viruses. 
DENV and ZIKV infections are transmitted by the same vector so the 
distribution areas naturally overlap. The symptoms can be similar and as 
they are closely related viruses the risk of misdiagnosis is obvious. 
Antibodies cross-react and then again in many endemic areas the facilities 
do not enable the detection of viral nucleic acids. Though there are 
shortcomings in specificity of the DENV NS1 Ag rapid tests, NS1 Ag ELISA 
tests have been shown to be highly specific. The NS1 Ag ELISA detection 
provides a promising method to differentiate DENV from ZIKV. What 
would be needed would be a ZIKV specific ZIKV-NS1 ag test. This is not yet 
on the market, but probably under development by various diagnostic 
companies. The potential of this kind of test is however depending on the 
kinetics, secretion and detectability of ZIKV NS1 Ag in patient samples, 
which is currently not known. As it has been seen in other infection 
markers, such as the viral RNA detection, DENV and ZIKV infections are 
not alike- this may be the case also with NS1 Ag. Currently many different 
test types are needed in order to detect and reliably confirm DENV or ZIKV 
infection. Overall the diagnostic method selection for flaviviruses has 
developed during the recent years and is now boosted to respond to the 
current needs for ZIKV diagnosis the problems with cross-reactions. When 
the research data so suggests, also the diagnostic guidelines will be 
changed. The accumulating evidence of the effects of Zika virus infection to 
foetus, and the detectability of ZIKV markers in pregnant women have 
already forced to re-evaluate the testing protocol for this specific group of 
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patients. Populations living in endemic regions might benefit from different 
procedures than travellers, who are often naïve for flavivirus infections. In 
future there may be specific diagnostic recommendations for different 
patient populations. 
To date we are heading towards an era when more and more sequence data 
will be available by NGS methods including whole genome sequences. Most 
probably this will reveal new viruses circulating and possibly some new 
disease associations. Yet, finding a virus sequence from a patient sample 
with NGS does not mean that it is associated to an acute infection. The 
symptoms of many arboviral infections resemble each other and 
traditionally specific diagnostics have been required for their detection. The 
detection has further been hampered the correct timing of the sampling if 
e.g. only serological methods have been available. Among flaviviruses and 
other viruses prone for cross-reactivity in serology, there also is risk of 
indistinct or even misdiagnosis. As NGS methodologies are in principle 
nucleic acid detection, also similar issues need to take into account as in 
traditional diagnostic viral nucleic acid detection, such as the timing of 
sampling in regard to onset of symptoms, sample type and the 
methodologies used for viral nucleic acid extraction.  
If fever patients suspected for arboviral infections patients were screened 
with NGS methods would we find viruses not known to circulate in certain 
areas? Another interesting insight would be to screen animals, for example 
encephalitic horses, as they might be the first sign of the circulating WNV. 
The lesson learned from Zika is that in very short period of time, a virus 
that we have neglected or at least not considered to have a big impact on 
public health may turn into an epidemic with high morbidity and symptoms 
that have not been seen previously. This emphasizes the need for efficient 
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